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Stereo- and regioisomers of a series of N,N-bis(alkanol)amine aryl ester derivatives have been prepared
and studied as multidrug resistance (MDR) modulators. The new compounds contain a 2-(methyl)propyl
chain combined with a 3-, 5- or 7-methylenes long chain and carry different aromatic ester portions.
Thus, these compounds have a methyl group on the 3-methylenes chain and represent branched ho-
mologues of previously studied derivatives. The introduction of the methyl group gives origin to a
stereogenic center and consequently to (R) and (S) enantiomers. In the pirarubicin uptake assay on K562/
DOX cell line these compounds showed good activity and efficacy and in many cases enantioselectivity
was observed. Docking studies confirmed the influence of the stereocenter on the interaction in the P-gp
pocket. The P-gp interaction mechanism and selectivity towards MRP1 and BCRP were also evaluated on
MDCK transfected cells overexpressing the three transporters. Almost all these compounds inhibited
both P-gp and BCRP, but only derivatives with specific structural characteristics showed MRP1 activity.
Moreover, two compounds, (S)-3 and (R)-7, showed the ability to induce collateral sensitivity (CS) against
MDR cells. Therefore, these two CS-promoting agents could be considered interesting leads for the
development of selective cytotoxic agents for drug-resistant cells.
© 2019 Elsevier Masson SAS. All rights reserved.ltidrug-resistance-associated
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served.1. Introduction
The anticancer chemotherapy is often impaired by the resis-
tance that cancer cells develop to cytotoxic drugs after an exposure
period. This resistance is calledmultidrug resistance (MDR) when it
is towards a multiplicity of structurally unrelated chemothera-
peutic drugs [1]. This cross-resistance is often due to an enhanced
energy dependent drug efflux, caused by the overexpression of
some transmembrane ATP-Binding Cassette (ABC) transporter
proteins. They are able to transport substrates through the mem-
brane against the concentration gradient [2,3] and are constitu-
tively expressed in many tissues playing important protective roles
through the regulation of the permeability of substances through
Chart 1. General structure of lead and newly designed compounds.
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cancer cells causes the reduction of the intracellular concentration
of antineoplastic agents. The transport proteins P-glycoprotein (P-
gp, ABCB1), Multidrug-Resistance-associated Protein-1 (MRP1,
ABCC1), and Breast Cancer Resistance Protein (BCRP, ABCG2) have
mainly been associated with MDR as they were found overex-
pressed in malignant tissues [5e7]. P-gp was the first ABC trans-
porter to be discovered playing a role in cancer cells drug resistance
[8,9]. In fact, it is overexpressed in several tumor cells as a result of
anticancer treatment and is responsible of an acquired resistance to
a number of structurally and mechanistically unrelated chemo-
therapeutic drugs [10,11]. MRP1 is overexpressed in cancer cells
that are not sensitive to several chemotherapeutic drugs such as
doxorubicin, methotrexate, cisplatin, etoposide and vincristine
[12]. The most recently discovered ABC efflux protein involved in
multidrug-resistance is BCRP. Its overexpression in many solid tu-
mors and leukemia, together with P-gp, impairs the efficacy of
many chemotherapeutic agents [13]. BCRP was also found
expressed in cancer stem cells causing their insensitivity to anti-
cancer drugs and consequently the long-lasting ineffectiveness of
many chemotherapy treatments [14,15]. P-gp and BCRP are the two
prevalent ABC efflux proteins placed at the blood-brain barrier
(BBB) and are the cause of the reduced BBB penetration of many
drugs, including antineoplastic agents, that are actively extruded
being substrate of these two efflux pumps [16,17].
A number of approaches to reverse MDR have been extensively
studied and the identification of ABC transporter protein inhibitors
has been considered an appropriate strategy. For this reason, many
modulators of these proteins have been synthesized over the past
few decades. These compounds are defined chemosensitizers, in
fact, when co-administered with anticancer agents which are
substrates of ABC transporters, they are able to restore their
effectiveness in resistant tumor cells [18,19].
In the last years several ABC transporter modulators have been
discovered; they are classified as first-, second- or third-generation,
according to their chronology and characteristics [20e23]. Several
of them have reached clinical trials [24e27], however no substan-
tial benefits have been established. The observed problems are
mainly due to their low potency and toxicity and also to cyto-
chrome isoform inhibitory effects [28]; even though the more
recently discovered MDR reversing agents show lower negative
properties.
Consequently, the search for more potent and efficacious MDR
reversers is still ongoing with the aim of overcoming some of the
obstacles concerning the use of chemosensitizers.
Compounds able to interact with ABC transporters present
different chemical structures; however, some general features for
the binding with these proteins have been identified, for instance
the presence of aromatic moieties and one or more protonable
nitrogen atoms, the ability of establishing hydrogen bond in-
teractions and high lipophilicity [29]. These features are in agree-
ment with the information collected on the structure of ABC
transporters suggesting that they are characterized, in particular for
P-gp, by large and polymorphous recognition sites where different
compounds can be accommodated in a plurality of binding modes
establishing hydrophobic interactions, hydrogen and pp, p-ion
bonds [30,31].
In the last years, high-throughput screening of pharmacological
libraries progressively identified also specific compounds which
were unexpectedly more effective as cytotoxic agents in drug-
resistant than in drug-sensitive cells [32e34]. Compounds
increasing reactive oxygen species (ROS), interfering with the en-
ergy metabolism and the synthesis of ATP and altering the mem-
brane fluidity exert selective toxicity in P-gp- and MRP1-
overexpressing cells. However, the molecular bases of thisparadoxical hypersensitivity, known as “collateral sensitivity” (CS),
as well as the development of rationally-designed new sensitizer
compounds are still under intensive investigation [35,36].
In previous papers we described the design and synthesis, and
in vitro studies of many series of MDR modulators characterized by
the presence of a basic nitrogen atom connected to two different
aromatic ester portions by two linkers with different length and
flexibility, such as polymethylenic chains or cyclohexane rings
[37,38]. In particular, several N,N-bis(alkanol)amine aryl esters
were synthesized; these compounds were characterized by
different combinations of aromatic ester residues connected to the
N-methylated basic portion by two polymethylenic chains of vari-
able length. Most of the synthesized compounds showed to be
potent and efficacious P-gp-dependent MDR reversers [37e42].
Some combinations of aromatic moieties and spacers seem to be
very positive; in fact, the (E)-3-(3,4,5-trimethoxyphenyl)vinyl
moiety with the 3,4,5-trimethoxyphenyl or the anthracene resi-
dues, and spacers of a total length of 6, 8 or 10 methylenes, gave
interesting results (compounds I-X, structure A, Chart 1).
In the present study we explored the consequence of the
modification of a three methylenes chain by the introduction of a
methyl group on the position 2. The steric hindrance introduced in
the chain could influence the bindingmode of these derivatives and
also prevent the enzymatic hydrolysis of the corresponding ester
function. As a matter of fact, in a previous study [42] it was
observed that in a series of derivatives with two chains of different
length, the hydrolysis occurs, in particular, when the ester group
was carried by a 3-methylenes N-alkyl chain. Moreover, this
modification gives origin to a stereogenic center and the two
possible enantiomers (R) and (S) could show different biological
activity. For this purpose, we synthesized a new series of com-
pounds with a 2-(methyl)propyl chain combined with a 3-, 5- or 7-
methylenes long chain, in order to connect the two aromatic
moieties with spacers of 6, 8 or 10 methylenes total length. All the
possible stereo- and regioisomers were obtained (compounds
1e12, structure B, Chart 1).
The new derivatives were studied on the doxorubicin-resistant
erythroleukemia K562 cell line (K562/DOX) to evaluate their
reversal activity by the pirarubicin uptake assay. Molecular docking
simulation studies were performed in order to identify the binding
mode of these compounds in the P-gp binding pocket.
The compounds were also studied to evaluate their P-gp inter-
action profile and selectivity towards two other ABC transporters,
MRP1 and BCRP. For these studies Madin-Darby Canine Kidney
(MDCK) transfected cells were used (MDCK-MDR1, MDCK-MRP1
and MDCK-BCRP cells overexpressing P-gp, MRP1 and BCRP,
respectively). Among the compounds displaying the best P-gp ac-
tivity and selectivity profile in these tests, the enantiomers (R)-3
and (R)-7 were selected for the co-administration study in the
presence of doxorubicin in MDCK-MDR1 cells. This study has been
performed in order to confirm the ability of these compounds to
reverse MDR, restoring the access of the chemotherapeutic drug
E. Teodori et al. / European Journal of Medicinal Chemistry 182 (2019) 111655 3into the cells. Moreover, collateral sensitivity studies were per-
formed for all compounds 1e12 onMDCK-MDR1, MDCK-MRP1 cells
and on the parental MDCK cells, in order to evaluate the selective
cytotoxicity of the synthesized compounds towards cells over-
expressing the two pumps P-gp and MRP1. Two compounds were
able to selectively kill MDR cells without cytotoxic effects towards
the parental cells. They can be considered as CS-promoting agents
and were further studied for their effect on the intracellular ROS
level.
Finally, the stability of this series of molecules towards hydro-
lysis was evaluated. In fact, the presence of the ester groups, in
particular, can compromise the stability of these compounds to-
wards plasma enzymes. For this purpose, a series of experiments in
phosphate buffer solution (PBS) and human plasma were per-
formed and the degradation profiles were evaluated.2. Chemistry
The reaction pathways used to synthesize the (R) enantiomers of
compounds 1e12 are reported in Scheme 1. The (S) bromoesters
13e15 were obtained by esterification of the commercially avail-
able chiral synthon (S)-3-bromo-2-(methyl)propan-1-ol with (E)-
3-(3,4,5-trimethoxyphenyl)acrylic acid, 3,4,5-trimethoxybenzoic
acid or anthracene-9-carboxylic acid. To obtain the desired ester,
the mixture of carboxylic acid and bromoalkyl alcohol was treated
with the activating agent EDCI, in the presence of DMAP in anhy-
drous CH2Cl2, or the suitable acid was transformed in the corre-
sponding acyl chloride by reactionwith SOCl2 in ethanol-free CHCl3Scheme 1. Reagents and conditions: (I) SOCl2, ethanol-free CHCl3 or EDCI, DMAP, an. CH
(n¼ 3,5,7), K2CO3, CH3CN; (IV) HCOOH/HCHO; (V) Ar1COCl, ethanol-free CHCl3 or Ar1COOH, E
from (R)-3-bromo-2-(methyl)propan-1-ol and following the same procedures (see the Expe(see Experimental section for details). The (S) bromoalkyl esters
13e15 were transformed in the corresponding (S) derivatives
16e18 with NaI in acetone, to obtain higher yields in the next re-
action. The (S) enantiomers 16e18 were then transformed into the
(R) secondary amines 19e27 by reaction with the commercially
available amino alcohols, 3-aminopropan-1-ol and 5-
aminopentan-1-ol, or the already reported 7-aminoheptan-1-ol
[43], using standard procedures. The absolute configuration
assigned to stereocenters changes by passing from iodo to amino
derivatives due to the different priority of the groups linked to the
stereogenic center. The (R) secondary amines were then alkylated
by reductive methylation with HCOOH/HCHO to give the corre-
sponding tertiary amines 28e36. Title compounds (R) 1e12 were
eventually obtained by reaction of (R) 28e36 with the appropriate
carboxylic acid in the presence of EDCI and DMAP in anhydrous
CH2Cl2, or by the corresponding acyl chloride obtained as described
before. The proper acids used are the same as described above: (E)-
3-(3,4,5-trimethoxyphenyl)acrylic acid, 3,4,5-trimethoxybenzoic
acid and anthracene-9-carboxylic acid. The (S) enantiomers of
compounds 1e12 were obtained starting from (R)-3-bromo-2-
(methyl)propan-1-ol and following the same procedures described
for the (R) enantiomers. For biological tests, all compounds were
transformed into HCl salts.
The enantiomeric excess (ee) of (R) and (S) enantiomers of
compounds 1e12 was assessed by enantioselective liquid chro-
matography coupled with diode array detector (LC-DAD) analysis.
To perform this analysis, different elution conditions were
employed (see Experimental section). All enantiomers showed2Cl2; for details, see the Experimental section; (II) NaI, acetone; (III) H2N(CH2)nOH
DCI, DMAP, an. CH2Cl2. The (S) enantiomers of compounds 1e12were obtained starting
rimental section).
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method, except compounds 4, 7 and 12 whose enantiomer pairs
(R)/(S) did not reach a sufficient resolution to assess their ee values;
anyway, since the synthetic pathway and the used enantiomeric
reagents were common for all products, it was reasonable that also
these compounds maintained the same enantiomeric excess
(95%).
3. Results
3.1. Modulation of pirarubicin uptake on K562/DOX cells
Compounds (R) and (S) 1e12 were studied for the P-gp modu-
lating activity by the pirarubicin uptake assay on K562/DOX
doxorubicin resistant cells, that overexpress only the membrane
glycoprotein P-gp [44e48], following protocols reported in previ-
ous papers [49,50].
The results obtained are reported in Table 1 together with those
of the corresponding previously synthetized compounds (I-X) with
an achiral threemethylenes chain, and verapamil, used as reference
compound. The data reported in Table 1 indicate that all the new
compounds inhibited the P-gp activity with high potency since
their [I]0.5 values fell in the nanomolar range; in addition, in many
cases these compounds completely reversed P-gp-dependent
pirarubicin extrusion (amax close to 1). Their potency and affinity
values were higher than those of the reference compound verap-
amil. A thorough analysis of the results indicated that the activity
([I]0.5) is influenced by the length of the linear chain (n value) and
only in part by the combination of the aromatic residues. In most
cases the two (R) and (S) enantiomers showed different potency
values although there is no regular trend in the behavior of the two
enantiomers. In fact, the (S) enantiomer was often the most potent,
but not in the case of compounds 2 and 3, that showed an inverted
enantioselectivity, and compounds 7, 9, 10 and 11 that showed
almost equally active (R) and (S) enantiomers. In any case, the in-
fluence of the stereogenic center on the activity of these com-
pounds wasmore or less pronounced depending on the total length
of the molecule. In fact, in the set with n¼ 3 (1e4), the two en-
antiomers were in general more potent than the corresponding
achiral compound with the same length and residues, particularly
in the case of the two enantiomers of 1 (compare I [I]0.5¼ 0.60 mM
with (R)-1 and (S)-1 [I]0.5¼ 0.14 and 0.09 mM, respectively). In the
set with n¼ 5 (5e8), the eutomer (the most active enantiomer) (S)-
5 showed a [I]0.5 value lower than that of the corresponding achiral
analogue III ([I]0.5¼ 0.08 mM and 0.27 mM, respectively). In the
other cases the activity of the achiral analogues was equally or
slightly higher than that of the eutomers (compare IV vs (S)-7, V vs
(S)-6, VI vs (S)-8). Regarding the set with n¼ 7 (9e12), all the
achiral derivatives, VII-X, were always more potent than the two
enantiomers of the corresponding chiral compounds (VII vs (R) and
(S) 9, VIII vs (R) and (S) 11, IX vs (R) and (S) 10, X vs (R) and (S) 12).
For what concerns the ester groups, the activity is not much
affected by the nature of the aromatic groups; in fact, there is no
regular trend for the influence of the type and the relative position
of the aromatic moieties. Anyway, within each set the combination
of the aromatic residues influences the enantioselectivity. In fact, in
the set with n¼ 3, the two eutomers of the regioisomers 1 and 3
showed an opposite configuration, (S)-1 and (R)-3, and different
enantioselectivity, since the eudismic ratios (ER, here defined for
sake of clarity as the ratio between the [I]0.5 of the (R) enantiomer
and the [I]0.5 of the (S) one) are 1.5 and 0.2, respectively. Com-
pounds 2 and 4 showed similar behavior even if, also in this case,
the enantioselectivity is inverted and the two eutomers are (R)-2
and (S)-4. In the set with n¼ 5 the eutomers of compounds with
the (E)-3-(3,4,5-trimethoxyphenyl)vinyl moiety on the 2-(methyl)propyl chain were more potent than those of the corresponding
regioisomers with this group on the 5-methylenes chain (compare
(S)-5 vs (S)-7 and (S)-6 vs (S)-8). The regioisomers of the set with
n¼ 7 showed instead a different behavior since the more potent
compounds have the (E)-3-(3,4,5-trimethoxyphenyl)vinyl moiety
on the 7-methylenes chain (compare (S)-9 vs (S)-11 and (S)-10 vs
(S)-12). In particular, the eutomer (S)-12 was 11 times more potent
than (S)-10 ([I]0.5¼ 0.08 mM and 0.89 mM. Moreover, in this set, the
two enantiomers were almost equally potent except for compound
12 (ER¼ 2.5).
As regards the efficacy, these compounds showed amax values
between 0.65 and 0.99 indicating that were able to reverse P-gp-
dependent pirarubicin extrusion with rather high amount and in
some cases the resistancewas even completely reversed (amax close
to 1).
Altogether, these results suggest that a methyl group at the
stereogenic center of the 3-methylenes linker differently influences
the activity of these compounds depending on the total length of
the molecule. In fact, the presence of this group exerts a favourable
effect, in comparison with the corresponding achiral derivatives, in
compounds with n¼ 3 (compare 1e4 vs I and II); on the contrary,
this feature appears to have lower influence on the activity for
compounds with a 5-methylenes chain (compare 5e8 vs III-VI),
and is definitely not productive for compounds with a 7-
methylenes chain (compare 9e12 vs VII-X). On the other hand, it
is important to note that, as reported above, the achiral compounds
with a total spacer of 10 methylenes (compounds VII-X) showed a
very good profile both in terms of potency and efficacy with all
combinations of aromatic groups; molecular modeling studies
indicated that these molecules are able to interact in a productive
manner with the P-gp interaction site [42]. In these newmolecules
themethyl group on the stereogenic center apparently prevents the
best interaction of this set of compounds with the protein binding
region.
3.2. Molecular modeling studies
Docking studies were performed to investigate the interaction
mode of the new compounds in the P-gp binding pocket and to
elucidate the influence of the stereocenter on their P-gp-inhibitory
activity. For this purpose, MolSoft was used to perform a flexible
docking calculation in order to predict the correct binding geom-
etry, the potential binding pocket of the protein, scoring functions
and the bond types of the enantiomers with the surrounding amino
acid binding pocket [51]. Molecular docking studies were per-
formed into 3D crystal of human P-gp (PDB code 6C0V) [52] and the
binding region of our compounds was identified based on 3D
crystal structure of Mus musculus P-gp in complex with the P-gp
inhibitor BDE-100 (PDB code 4XWK) [53]. The bindingmodewithin
the P-gp binding region of compounds 1e12 was compared with
that of the corresponding achiral analogues I-X (Table 1), studied
with the same method. The docking energy scores of the tested
compounds are listed in Table 1. Fig. 1 describes the correlation
between the calculated binding free energies (DG) and the activ-
ities of the compounds on the pirarubicin uptake test, expressed as
p[I]0.5. The correlation coefficient (R2) value in Fig. 1 suggests that
computational analysis results strictly correlate with the biological
activities on the pirarubicin uptake test.
MolSoft docking results revealed that all achiral and chiral
compounds showed moderate to high binding affinity towards P-
gp with binding energy ranging from 3.80 to 25.06 kcal/mol.
They identified a binding region with two pockets: one (site 1) is
located in the inner central chamber surrounded by hydrophobic
residues, which is the common binding site of ligands in complex
crystal structures, while site 2 is a deeper binding site where the
Table 1
MDR-reversing activity of enantiomers of the target compounds 1e12 evaluated on doxorubicin-resistant erythroleukemia K562 cells (K562/DOX) by the pirarubicin uptake
assay.
Compd Struct. Conf. n Ar Ar1 [I]0.5 mMa ERb amaxc dDG (Kcal/mol)
(R)-1 B R 3 a b 0.14± 0.03 1.5 0.99± 0.01 15.94
(S)-1 B S 3 a b 0.09± 0.07 0.75± 0.04 16.66
(R)-3 B R 3 b a 0.11± 0.02 0.2 0.99± 0.01 16.12
(S)-3 B S 3 b a 0.54± 0.15 0.89± 0.10 5.90
Ie A 3 a b 0.60± 0.15 0.90± 0.05 5.50
(R)-2 B R 3 a c 0.08± 0.03 0.4 0.99± 0.10 16.80
(S)-2 B S 3 a c 0.18± 0.02 0.79± 0.09 15.86
(R)-4 B R 3 c a 0.17± 0.04 4.2 0.80± 0.06 15.90
(S)-4 B S 3 c a 0.04± 0.01 0.99± 0.01 20.30
IIe A 3 a c 0.18± 0.05 0.78± 0.03 15.30
(R)-5 B R 5 a b 0.40± 0.01 5.0 0.99± 0.30 7.10
(S)-5 B S 5 a b 0.08± 0.02 0.99± 0.01 16.90
IIIf A 5 a b 0.27± 0.05 0.97± 0.02 9.10
(R)-7 B R 5 b a 0.35± 0.10 1.4 0.72± 0.07 9.90
(S)-7 B S 5 b a 0.24± 0.07 0.75± 0.06 10.20
IVf A 5 b a 0.12± 0.02 0.99± 0.01 16.80
(R)-6 B R 5 a c 0.08± 0.03 2.6 0.88± 0.03 17.10
(S)-6 B S 5 a c 0.03± 0.007 0.79± 0.01 22.70
Vf A 5 a c 0.04± 0.02 0.94± 0.03 20.00
(R)-8 B R 5 c a 0.23± 0.08 2.9 0.89± 0.06 9.56
(S)-8 B S 5 c a 0.08± 0.02 0.75± 0.05 17.50
VIf A 5 c a 0.04± 0.01 0.98± 0.02 19.80
(R)-9 B R 7 a b 0.59± 0.17 1.5 0.81± 0.05 5.70
(S)-9 B S 7 a b 0.38± 0.11 0.74± 0.05 8.70
VIIg A 7 a b 0.08± 0.03 0.97± 0.03 18.00
(R)-11 B R 7 b a 0.12± 0.04 1 0.83± 0.05 16.30
(S)-11 B S 7 b a 0.13± 0.05 0.70± 0.04 16.50
VIIIg A 7 b a 0.06± 0.02 0.99± 0.01 19.30
(R)-10 B R 7 a c 0.97± 0.28 1.1 0.65± 0.07 3.80
(S)-10 B S 7 a c 0.89± 0.21 0.80± 0.05 4.00
IXg A 7 a c 0.04± 0.01 0.88± 0.08 20.50
(R)-12 B R 7 c a 0.20± 0.06 2.5 0.93± 0.05 10.10
(S)-12 B S 7 c a 0.08± 0.02 0.99± 0.01 20.74
Xg A 7 c a 0.01± 0.003 0.93± 0.04 25.06
Ver. 1.60± 0.30 0.70± 0.07 1.80
a Potency of the MDR-modulator: concentration of the compound that causes a 50% increase in the nuclear concentration of pirarubicin (a¼ 0.5).
b ER¼ eudismic ratio ([I]0.5 (R) enantiomer/[I]0.5 (S) enantiomer).
c Efficacy of the MDR-modulator: maximum increase that can be obtained in the nuclear concentration of pirarubicin in resistant cells; a value varies between 0 (in the
absence of the modulator) and 1 (when the amount of pirarubicin in resistant cells is the same as in sensitive cells). Results are expressed as the mean± SE of three inde-
pendent experiments done at least three times.
d Predicted binding affinity.
e See ref. 37.
f See ref. 40.
g See ref. 42.
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establish interactions with both hydrophobic and polar residues
[54], as showed in Fig. 2. The achiral compound X showed the
lowest binding energy computational value (DG¼25.06 kcal/
mol). It interacts at both the P-gp binding sites forming three p-
stacking bonds with the three aromatic rings of the anthracene
moiety and phenylalanine residues (site 1), and hydrophobic in-
teractions with isoleucine, leucine, phenylalanine and valine resi-
dues (sites 1 and 2) (Fig. 3 A).
On the contrary, molecular docking of chiral compounds
showed that they occupy only a part of the binding region estab-
lishing interactions with different binding pocket residues than the
achiral compounds. In particular, we observed that all chiral com-
pounds do not reach the same binding poses of the best achiral
derivative (Fig. 3), probably due to the presence of themethyl groupon one of the two linkers. Moreover, the presence of the stereo-
center influences the pose of the enantiomer couples. As an
example, in Fig. 3 B we observed how the two enantiomers (R)-6
and (S)-6 achieved similar poses showing comparable binding free
energy values (Table 1). Differently, the two enantiomers (R)-5 and
(S)-5 showed different poses and binding energies (Fig. 3C and
Table 1), in accordance with the results on the pirarubicin uptake
test where the two enantiomers showed an ER¼ 5.0 (Table 1).
In conclusion, we can therefore state that chiral molecules
interact at the P-gp binding pocket in different ways with respect to
achiral analogues, in particular, with a 7-methylene chain; the
latter derivatives, in fact, can reach easily the end of the pocket
forming important interactionswith Leu 225, Phe 193, 200 and 204,
and Val 338. Anyway, many chiral molecules are able to form strong
interactions with binding protein residues that are crucial for the
Fig. 1. Correlation between the calculated MolSoft tool binding free energies (DG) and
the experimental p[I]0.5 values, expressed as mM concentration, for P-gp that are re-
ported in Table 1.
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study.
3.3. Characterization of P-gp interacting profile and ABC
transporters selectivity on transfected MDCK cells
The new compounds were further studied on MDCK-MDR1
(Madin-Darby Canine Kidney-MDR1) cells overexpressing P-gp,
by inhibition of the transport of Calcein-AM, a profluorescent probe
that is a P-gp substrate.
The P-gp interaction mechanism of the compounds was also
investigated and, besides the P-gp potency assay on MDCK-MDR1
cells, other two combined assays were employed, as previously
reported [55]: 1) apparent permeability (Papp) determination (BA/
AB) in Caco-2 cell monolayer [56] which measures the ratio be-
tween two fluxes, BA, from the basolateral to apical compartments,Fig. 2. 3D representation of human P-gp in the lipid bilayer (green). MolSoft program iden
surface surrounded by binding region residues represented with blue ball and sticks. (For int
Web version of this article.)that represents passive diffusion, and AB, from the apical to baso-
lateral compartments, that represents active transport; 2) ATP cell
depletion in cells overexpressing the transporter MDCK-MDR1 [57]
which measures the ATP consumption due to transport mediated
by the pump; generally, a substrate, being transported by the
pump, induces ATP cell depletion (unambiguous substrate, cate-
gory I), while a P-gp inhibitor does not induce ATP consumption.
(BA/AB)< 2 indicates that the compound can be considered an in-
hibitor, also taking into account the results of the ATPase assay and
Calcein-AM modulation, (BA/AB)> 2 indicates that the compound
is classified as a substrate [58,59]. However, another substrate
category (known as category IIB3) displaying a Papp value> 2 but
not inducing an ATP cell depletion is also reported [60].
Finally, the compounds were also studied on cells over-
expressing MRP1 (MDCK-MRP1 cells) or BCRP (MDCK-BCRP cells)
to evaluate their inhibitory activity toward two other ABC proteins,
MRP1 and BCRP, by the inhibition of the transport of Calcein-AM
(MRP1 substrate) or the fluorescent probe Hoechst 33342 (BCRP
substrate), respectively.
P-gp, MRP1 and BCRP expression levels were periodically ana-
lysed by immunoblotting analysis in MDCK-MDR1, MDCK-MRP1
and MDCK-BCRP cells, respectively, using tubulin as control of
equal protein loading. Details of the method and a representative
Western blot analysis are reported in the Supplementary data.
The results of the assays described above are reported in Table 2
together with those on verapamil, used as reference compound.
As shown in Table 2, all compounds were able to inhibit the P-gp
Calcein-AM transport with EC50 values ranging from 0.073 to
1.40 mM, indicating, in this assay, high or moderate activities on P-
gp. The EC50 values are, in some cases ((R)-3, (R)-7, (S)-7 and (S)-9)
lower than that of the reference compound verapamil
(EC50¼ 0.50 mM).
Stereochemistry does not seem to influence the P-gp inhibition
on MDCK-MDR1 cells of these compounds. In fact, in many cases
the two enantiomers showed similar EC50 values, or with a smalltified two sites inside the protein and predicted binding-pockets are shown in orange
erpretation of the references to colour in this figure legend, the reader is referred to the
Fig. 3. 3D representation of human P-gp binding region (orange) inside the lipid bilayer (green). (A) Blue balls and sticks represent residues of P-gp binding pocket with the best
active achiral compound X in orange. (B-C) Blue balls and sticks represent residues of P-gp binding pocket with enantiomers (R)-6 (magenta) and (S)-6 (green), (panel B) and (R)-5
(red) and (S)-5 (yellow), (panel C). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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mers (R)-3 and (S)-3 that showed a difference of 7.5 times
(EC50¼ 0.073 mM and 0.55 mM, respectively). Anyway, also in this
test, there is a non-homogeneous S/R preference since the eutomers
of compounds 1 and 3 showed a R absolute configuration while
those of compounds 7, 9 and 10 showed a S absolute configuration.
The total length of the molecule does not seem to influence this
kind of activity while the nature of the aromatic residues partly
affects the activity; in fact, compounds with EC50 values lower than,
or roughly equal to 0.5 mM ((R)-3, (S)-3, (R)-7, (S)-7, (S)-9 and (S)-11)
have the combination of the (E)-3-(3,4,5-trimethoxyphenyl)vinyl
moiety with the 3,4,5-trimethoxyphenyl one, while the presence of
the anthracene residue gave higher EC50 values ranging from 0.76
to 1.40 mM.
In this test, these compounds showed a lightly different profile
than that in the pirarubicin uptake test, but it must be considered
that the cell lines used for the two assays are different.
All compounds, except (R)-5, were able to inhibit BCRP but with
activities lower than that of verapamil (EC50¼ 0.9 mM). Also in this
case stereochemistry has low influence on the activity with some
exception (1, 2, 5, 6, 7). In particular, enantiomer (S)-5 was able to
inhibit BCRP (EC50¼ 4.2 mM) while (R)-5 was completely inactive
up to a 100 mM.
The inhibitory activity on MRP1 is influenced by the nature of
the aromatic residues since all anthracene derivatives were inactive
on this transporter; the other compounds were able to inhibit
MRP1 Calcein-AM transport with potencies higher than that ofverapamil, with the exception of compounds (S)-1, (R)-3, (S)-3 and
(S)-5. Also in this case the stereochemistry has little influence on
the activity, but not in the case of 1, 5, 9 and 3, where only enan-
tiomer (R)-3was able to inhibit MRP1 (EC50¼ 7.3 mM) and (S)-3was
completely inactive.
The apparent permeability values (Papp) indicated that all com-
pounds had a BA/AB ratio> 2 and were not able to induce ATP
consumption, with the exception of compound (S)-1; therefore, (S)-
1 could be considered a P-gp unambiguous substrate (category I)
and all the other compounds were not transported substrates
(category IIB3) [60].3.4. Co-administration assay
Compounds that displayed the best P-gp activity in the test on P-
gp transfected cells (MDCK-MDR1) ((R)-3, EC50¼ 0.073 mM) or
endowed with a good P-gp activity and selectivity profile towards
the other two sister proteins ((R)-7, EC50¼ 0.31 mM, 5.8 mM, 41 mM
vs P-gp, MRP1 and BCRP, respectively), have been tested in co-
administration with the antineoplastic drug doxorubicin at 10 mM
in MDCK cells overexpressing MDR1. Doxorubicin alone did not
exert cytotoxicity effects since it is a P-gp substrate and was unable
to overcome MDR1; when doxorubicin was added in the presence
of (R)-3 and (R)-7, its activity was restored because of the inhibition
of the pump carried out by the two compounds. (R)-3 and (R)-7
were tested at two different doses in a range near their EC50 values
(100 nM and 1 mM for (R)-3, and 500 nM and 1 mM for (R)-7)
Table 2
Biological results of enantiomers 1e12: inhibition activity on MDCK-MDR1, MDCK-MRP1 andMDCK-BCRP cells overexpressing each transporter P-gp, MRP1 and BCRP, ATP cell
depletion in MDCK-MDR1 and apparent permeability (Papp) determination (BA/AB) in Caco-2 cell monolayer..
Compd
Conf n Ar Ar1 EC50 mMa ATP cell depletion Pappb
P-gp MRP1 BCRP
(R)-1 R 3 a b 0.71± 0.10 5.6± 1.12 33.5± 5.8 no 7.6
(S)-1 S 3 a b 1.38± 0.20 12.7± 2.5 3.7± 0.70 yesc 5
(R)-3 R 3 b a 0.073± 0.01 7.3± 1.4 9.5± 1.90 no 6.9
(S)-3 S 3 b a 0.55± 0.10 NA 6.4± 1.30 no 7.5
(R)-2 R 3 a c 0.95± 0.20 NA 5.9± 1.20 no 13
(S)-2 S 3 a c 0.91± 0.20 NA 2.3± 0.40 no 30
(R)-4 R 3 c a 0.96± 0.10 NA 6.8± 1.36 no 7.5
(S)-4 S 3 c a 0.91± 0.18 NA 11.0± 2.0 no 15
(R)-5 R 5 a b 1.00± 0.16 3.9± 0.77 NA no 5
(S)-5 S 5 a b 1.10± 0.20 10.1± 2.0 4.2± 0.80 no 8
(R)-7 R 5 b a 0.31± 0.05 5.8± 1.20 41.0± 8.2 no 6.5
(S)-7 S 5 b a 0.11± 0.02 4.4± 0.88 8.1± 1.62 no 6.6
(R)-6 R 5 a c 0.72± 0.10 NA 2.3± 0.46 no >20
(S)-6 S 5 a c 0.69± 0.14 NA 4.7± 0.90 no >20
(R)-8 R 5 c a 0.81± 0.16 NA 4.6± 0.92 no 18
(S)-8 S 5 c a 0.76± 0.10 NA 4.6± 0.90 no 15
(R)-9 R 7 a b 0.82± 0.15 3.7± 0.72 4.7± 0.84 no 16
(S)-9 S 7 a b 0.32± 0.05 1.9± 0.32 2.3± 0.40 no 17
(R)-11 R 7 b a 0.65± 0.13 3.5± 0.70 4.3± 0.80 no 10.3
(S)-11 S 7 b a 0.55± 0.10 2.8± 0.60 2.5± 0.50 no 14.4
(R)-10 R 7 a c 1.40± 0.20 NA 6.4± 1.20 no 20
(S)-10 S 7 a c 0.93± 0.18 NA 5.6± 1.12 no 23
(R)-12 R 7 c a 0.99± 0.19 NA 6.2± 1.24 no 6.1
(S)-12 S 7 c a 1.04± 0.20 NA 7.2± 1.40 no 9.2
Ver. 0.50± 0.1 6.8± 3.0 0.9± 0.20 yesd 18
a Values are the mean ± SEM of two independent experiments, with samples in triplicate.
b Apparent permeability estimation: values are from two independent experiments, with samples in duplicate.
c Percentage of the effect at a concentration of 10 mM (20%).
d Percentage of the effect at a concentration of 1 mM (20%). NA¼ not active.
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respectively (Fig. 4).
3.5. Collateral sensitivity study and effect on ROS production
All compounds have been tested for their ability to induce
collateral sensitivity (CS) against MDR1 or MRP1. CS is a newFig. 4. In vitro cell growth experiments performed on MDCK-MDR1 cells in the presence o
doses alone and in co-administration with Doxo. Each bar represents the mean ± SEM of tstrategy to overcome MDR by using compounds able to selectively
kill MDR cells without cytotoxic effects towards the parental cells
[35,36,61e63]. CS can be quantitatively assessed by measuring the
selectivity ratio (SR) between the cytotoxicity of the compound vs
parental cells and its cytotoxicity vs MDR-derived cells (EC50
parental/EC50 MDR). SR< 1 indicates that MDR cells are resistant to
the ligand that is probably transported by the MDR pump; SR> 1f 10 mM doxorubicin (Doxo) alone (white bar), compounds (R)-3 and (R)-7 at different
wo experiments performed in triplicate. One-way ANOVA analysis: **p < 0.005.
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than that vs parental cells. A compound displaying a SR 2 is
generally defined as CS-promoting agent.
Among the tested series, only compounds (S)-3 and (R)-7 dis-
played a SR> 2 towards MDR pumps.
Indeed, (S)-3 has a SR¼ 2.5 vsMDCK-MDR1 cells (EC50¼100 mM
onMDCK-wt cells and EC50¼ 40 mMonMDCK-MDR1 cells) and (R)-
7 has a SR¼ 8.5 vs MDCK-MRP1 cells (EC50¼100 mM on MDCK-wt
cells and EC50¼11.7 mMonMDCK-MRP1 cells). Therefore, (S)-3 and
(R)-7 can be considered as CS-promoting agents on P-gp and MRP1,
respectively.
One of the mechanisms at the basis of CS is the increased pro-
duction of ROS in cells overexpressing ABC transporters [35]. To
investigatewhether this mechanismwas involved in the sensitizing
effects elicited by (S)-3 and (R)-7, the intracellular ROS in MDCK-
MDR1, for compound (S)-3, and MDCK-MRP1 cells for compound
(R)-7, was measured. (S)-3 and (R)-7 significantly increased intra-
cellular ROS in MDCK-MDR1 (Fig. 5A) and MDCK-MRP1 (Fig. 5C)
cells, respectively. To verify whether the increased ROS mediated
the reduction in cell viability elicited by the compounds, the cells
were co-incubated with (S)-3 or (R)-7 plus the ROS scavenger N-
acetyl-cysteine (NAC), at a concentration that abrogated the in-
crease in ROS induced by the compounds (Fig. 5 A and C). While (S)-
3 or (R)-7 alone significantly decreased cell viability, the co-
incubation with NAC partially but significantly rescued cell
viability (Fig. 5 B and D).
These results suggest that at least part of the mechanism at the
basis of the collateral sensitivity of (S)-3 or (R)-7 relies on theFig. 5. Effects of (S)-3 and (R)-7 on MDCK-MDR1increased production of ROS in MDR1-and MRP1-overexpressing
cells, respectively.
MDCK-MDR1 cells (panels A and B) were grown for 24 h in fresh
medium (ctrl) or with 500 nM (S)-3 alone or in the presence of the
ROS scavenger N-acetyl-cysteine (NAC, 10mM). MDCK-MRP1 cells
(panels C and D) were grown for 24 h in freshmedium (ctrl) or with
500 nM (R)-7 alone or in the presence of the ROS scavenger N-
acetyl-cysteine (NAC, 10 mM). Panels A and C: ROS were measured
fluorimetrically, in duplicates (n ¼ 3). Data are presented as
means ± SD. ****p< 0.0001 vs ctrl; p< 0.0001: NAC-treated
cells vs (S)-3 and (R)-7, respectively. Panels B and D: cell viability
was measured with a chemiluminescence-based assay, in quadru-
plicates (n ¼ 3). Data are presented as means ± SD. ****p < 0.0001:
vs ctrl; p < 0.001: NAC-treated cells vs (S)-3 and (R)-7, respec-
tively [63].
3.6. Chemical stability test
The chemical stability of compounds 1e12 was evaluated in
phosphate buffer solution (PBS) and in human plasma samples to
verify if spontaneous or enzymatic hydrolysis occurs. The analyses
were carried out by LC-MS/MS method operating in Multiple Re-
action Monitoring (MRM) mode [64].
The LC-MS/MS system and experimental conditions used are
reported in the Supplementary data.
The solution stability of each compound was verified by moni-
toring the variation of analyte concentration at different incubation
times in PBS and human plasma samples. The evaluation of theand MDCK-MRP1 ROS levels and viability.
Table 3
Half-life (t1/2) values of reference and studied compounds in PBS e human plasma samples.
Compd PBS t1/2± error (min) Human plasma t1/2± error (min) Compd PBS t1/2± error (min) Human plasma t1/2± error (min)
KEE n.d. 107± 16
(R)-1 240 117± 10 (R)-7 240 240
(S)-1 240 29± 7 (S)-7 240 240
(R)-2 240 240 (R)-8 240 240
(S)-2 240 240 (S)-8 240 240
(R)-3 240 54± 12 (R)-9 240 74± 27
(S)-3 240 240 (S)-9 240 30± 9
(R)-4 240 240 (R)-10 240 240
(S)-4 240 240 (S)-10 240 240
(R)-5 240 29± 15 (R)-11 240 240
(S)-5 240 18± 6 (S)-11 240 240
(R)-6 240 240 (R)-12 240 240
(S)-6 240 240 (S)-12 240 240
n.d.: not determined.
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ported in the Supplementary data. The obtained results demon-
strated that all the compounds were stable in PBS andmost of them
also in human plasma. In fact, only the degradation plots, in human
plasma, of (R)-1, (S)-1, (R)-3, (R)-5, (S)-5, (R)-9 and (S)-9 showed a
significant decay rate (k value2 103 ln mM/min), and their
calculated half-life values varied between 18 and 117min (Table 3).
As an example, the human plasma degradation plots of the enan-
tiomer couples (R)-1 and (S)-1 are reported in Fig. 6. The plots of all
compounds are reported in the Supplementary data (Figs. S2eS25).
The half-life value of the reference compound ketoprofene ethyl-
ester (KEE) indicated that the human batch employed was enzy-
matically active (half-life < 2 h) [65].
The k values of the stable compounds were close to 0; therefore,
extremely high half-life values can be calculated for theseFig. 6. Degradation plots of the enantiomers couples (R)-1 (top), (S)-1 (bottom) in PBS (squa
to colour in this figure legend, the reader is referred to the Web version of this article.)derivatives. Since 240min is the maximum time of observation in
our experimental protocol, it is possible to assume that their half-
life values could be equal or greater than 240min.
The degradation products of compounds (R)-1, (S)-1, (R)-3, (R)-5,
(S)-5, (R)-9 and (S)-9were also examined to determine the possible
mechanism of the enzymatic hydrolysis. The results proved that
these compounds were hydrolyzed at the ester group linked to the
(E)-3-(3,4,5-trimethoxyphenyl)vinyl moiety (a, see Chart 1), with
formation of the corresponding N-alkyl alcohol and of the (E)-3-
(3,4,5-trimethoxyphenyl)acrylic acid (Supplementary data,
Fig. S26). Noteworthy is that the hydrolysis takes place only when
the (E)-3-(3,4,5-trimethoxyphenyl)vinyl ester is linked to the three
methylenes 2-(methyl)propyl chain and combined with the 3,4,5-
trimethoxybenzoic moiety (b, see Chart 1) (e.g. (R)-1 and (S)-1).
As a matter of fact, the enzyme activity is prevented when the (E)-re blue) and human plasma (red triangle) samples. (For interpretation of the references
Fig. 7. Degradation plots of the enantiomers couples (R)-3 (top), (S)-3 (bottom) in PBS (square blue) and human plasma (red triangle) samples. (For interpretation of the references
to colour in this figure legend, the reader is referred to the Web version of this article.)
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anthracene residue (c, see Chart 1) (i.e. (R)-2 and (S)-2). This
behavior was already highlighted in the previously studied achiral
series with a 3-methylenes chain [42] (see the achiral derivative I)
and it is therefore confirmed also in this chiral series carrying a
branched 3-methylenes chain (2-(methyl)propyl chain). However,
this feature depends on the configuration of the stereogenic center,
in fact, the (S) enantiomers always showed a degradation rate
higher than the corresponding (R) ones (see (S)-1, (S)-5 and (S)-9)
(Table 3). On the contrary, (R)-3 and (S)-3, having the (E)-3-(3,4,5-
trimethoxyphenyl)vinyl moiety linked to the linear three methy-
lenes alkyl chain, showed a different behavior. As a matter of fact,
the (R) enantiomer suffers a remarkable degradation (t1/
2¼ 54± 12min) while the (S) one did not show a significant
enzymatic hydrolysis (Table 3 and Fig. 7).
4. Discussion
In this work we reported a new series of N,N-bis(alkanol)amine
aryl ester derivatives studied as MDR modulators. The new com-
pounds contain a 2-(methyl)propyl chain combined with a 3-, 5- or
7-methylenes long chain and bearing different aromatic ester
portions. These compounds represent branched homologues of
previously studied derivatives (I-X). The introduction of a methyl
group in these molecules gives origin to a stereogenic center and
consequently to (R) and (S) enantiomers.
The biological behavior of these compounds was studied by
various tests that allowed us to highlight different characteristics.
The MDR reversal activity was evaluated by the pirarubicin
uptake assay on doxorubicin-resistant erythroleukemia K562 cell
line (K562/DOX). In this test these compounds showed good
inhibitory activity with potency values ([I]0.5) in the nanomolar
range and, in general, completely reversed P-gp-dependentpirarubicin extrusion (amax close to 1). In most cases the (R) and (S)
isomers showed different potency values although there is no
regular trend in the behavior of the two enantiomers. In compari-
son with the corresponding achiral derivatives, the presence of the
methyl group on the stereogenic center appears to exert a clear
positive effect only in the set with n¼ 3, since these compounds
were in general more potent than the corresponding achiral de-
rivatives showing the same length and residues.
Docking simulations were employed to elucidate the influence
of the stereocenter on the binding mode of these compounds in the
P-gp pocket site. The chiral compounds appeared to have a binding
mode partly different from that of achiral ones, forming in-
teractions with different binding pocket residues. In particular, the
presence of the methyl group at the stereocenter prevents de-
rivatives with n¼ 7 from reaching the same binding poses of the
corresponding most active achiral derivatives; however, the added
methyl group is probably able to establish favourable interactions
for compounds with n¼ 3.
The P-gp interaction profile and selectivity towards MRP1 and
BCRP of the new compounds were investigated on MDCK trans-
fected cells overexpressing the transporters P-gp, MRP1 and BCRP.
In this test, all compounds were able to inhibit P-gp efflux ac-
tivity and small differences in activity and enantioselectivity were
observed throughout the series. These results are lightly different
from those found in the pirarubicin uptake test, but it must be kept
in mind that the cell lines used in these two tests are different
(Madin-Darby Canine Kidney (MDCK) transfected cells and
doxorubicin-resistant erythroleukemia K562 cells, respectively).
As for the P-gp-interacting profile, only compound (S)-1 can be
considered a P-gp unambiguous substrate (category I) whereas all
the other compounds were not transported substrates (category
IIB3).
The co-administration assay on the enantiomers (R)-3 and (R)-7
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since the activity of the anticancer drug in MDCK-MDR1 cells was
restored.
All compounds, except (R)-5, were able to inhibit BCRP, while
only molecules bearing the combination of the two aromatic
moieties (E)-3-(3,4,5-trimethoxyphenyl)vinyl and 3,4,5-
trimethoxyphenyl showed MRP1 inhibition activity. These results
confirmed the same outcome already found in our previous paper
[42], namely that the anthracene residue is not positive for the
MRP1 inhibition.
Of great interest was the ability to induce collateral sensitivity
showed by (S)-3 and (R)-7. Both compounds indeed can be
considered as CS-promoting agents towards MDR pumps, as they
proved to be able to selectively kill MDR cells (MDCK-MDR1 and
MDCK-MRP1 cells, respectively) without cytotoxic effects towards
the parental cells, displaying a SR> 2. The mechanism at the basis
of the collateral sensitivity of these two compounds relies at least in
part on the increased production of ROS in MDR1-and MRP1-
overexpressing cells, respectively.
Finally, most compounds of this new series of MDR inhibitors
were stable in PBS and human plasma, despite the presence of the
two ester groups. Only (R)-3 and the two enantiomers of com-
pounds 1, 5 and 9 showed a significant decay rate in the human
plasma; the hydrolysis occurs at the ester group linked to the (E)-3-
(3,4,5-trimethoxyphenyl)vinyl moiety and the degradation rate
depends on the configuration of the streocenter of the molecules.5. Conclusions
In this study we designed and synthesized a new series of N,N-
bis(alkanol)amine aryl esters bearing a chiral alkyl chain allowing
the identification of interesting MDR reversers. The presence of a
methyl group at the stereocenter causes in many cases enantiose-
lectivity, a characteristic that is not common among MDR trans-
porter protein ligands. Docking studies confirmed the influence of
the stereocenter on the interaction of these compounds in the P-gp
pocket.
Interestingly, nearly all these compounds were able to inhibit
both P-gp and BCRP; since these two transporter proteins were
often found co-expressed in several tumors, this behaviour could
be an interesting feature of this series of derivatives. The inhibitory
activity on MRP1 is influenced by the nature of the aromatic resi-
dues since all anthracene derivatives are inactive allowing us to
identify the molecular determinants for this activity.
Also noteworthy is the identification of two compounds, (S)-3
and (R)-7, able to induce collateral sensitivity (CS) against MDR1-
and MRP1-overexpressing cells. Therefore, these two compounds
can be considered as CS-promoting agents and could represent
interesting leads for the development of selective cytotoxic agents
for drug-resistant cells. In a biological perspective, these results are
remarkable at least for two reasons. First, it was possible to identify
two compounds, (S)-3 and (R)-7, that exhibited anti-cancer activity
in the low micromolar/nanomolar range, i.e. a range that are
comparable to most common chemotherapeutic drugs. Second,
while several sensitizers for MDR1-expressing cells have been
designed and tested at preclinical level, the number of sensitizers
effective against MRP1-expressing cells is significantly lower. Our
study provides a comprehensive view of synthesis, physical-
chemical properties and biological efficacy of two new potent and
MDR1/MRP1-expressing cells sensitizer compounds.
Taking altogether these results into account, this series of MDR
modulators seems very promising and deserves further investiga-
tion. Work is underway to expand structure activity relationships
and to improve potency and efficacy in this series of molecules.6. Experimental section
6.1. Chemistry
All melting points were taken on a Büchi apparatus and are
uncorrected. NMR spectra were recorded on a Bruker Avance 400
spectrometer (400MHz for 1H NMR, 100MHz for 13C). 1H and 13C
NMR spectra were measured at room temperature (25 C) in an
appropriate solvent. 1H and 13C chemical shifts are expressed in
ppm (d) referred to TMS. Spectral data are reported using the
following abbreviations: s¼ singlet, bs¼ broad singlet, d¼ doublet,
dd¼ doublet of doublets, t¼ triplet, m¼multiplet, and coupling
constants are reported in Hz, followed by integration. Chromato-
graphic separations were performed on a silica gel column by
gravity chromatography (Kieselgel 40, 0.063e0.200mm; Merck) or
flash chromatography (Kieselgel 40, 0.040e0.063mm; Merck).
Yields are given after purification, unless otherwise stated.
The enantiomeric excess (ee) and purity of final compounds
were determined by Agilent 1200 liquid chromatography system
composed by autosampler, binary pumps, column oven and diode-
array detector (LC-DAD) operating in UV range (210e400 nm). The
operating conditions were reported in Supplementary data.
High resolution mass spectrometry (HR-MS) analyses of final
compounds were performed with a Thermo Finnigan LTQ Orbitrap
mass spectrometer equipped with an electrospray ionization
source (ESI). The analyses were carried out introducing, via syringe
pump at 10 mLmin1, the sample solution (1.0 mg/mL in mQ
water:acetonitrile 50:50), in positive ionmode. These experimental
conditions allow the monitoring of protonated molecules of the
studied compounds ([MþH]þ species), that they were measured
with a proper dwell time to achieve 60,000 units of resolution at
Full Width at Half Maximum (FWHM). Elemental composition of
compounds was calculated on the basis of their measured accurate
masses, accepting only results with an attribution error less than
5 ppm and a not integer RDB (double bond/ring equivalents) value,
in order to consider only the protonated species [66].
When reactions were performed in anhydrous conditions, the
mixtures were maintained under nitrogen. Free bases (R) and (S)
1e12were transformed into the hydrochloride by treatment with a
solution of acetyl chloride (1.1 eq) in anhydrous CH3OH. The salts
were crystallized from abs. ethanol/petroleum ether. Compounds
were named following IUPAC rules as applied by ChemBioDraw
Ultra 14.0 software.
6.1.1. (S) (E)-3-Bromo-2-methylpropyl 3-(3,4,5-trimethoxyphenyl)
acrylate (S)-13
To a solution of 467.0mg (1.96mmol) of ((E)-3-(3,4,5-
trimethoxyphenyl)acrylic acid in 6mL of CHCl3 (free of ethanol),
0.25mL (3.9mmol) of SOCl2 were added and the solution was
stirred for 4 h at 60 C. The reaction mixture was cooled to rt, and
the solvent was removed under reduced pressure; the mixture was
then treated twice with cyclohexane and the solvent removed
under reduce pressure. The acyl chloride obtained was dissolved in
CHCl3 (free of ethanol), and (S)-3-bromo-2-(methyl)propan-1-ol
(0.20mL, 1.96mmol) was added. The mixture was maintained at
room temperature for 18 h and treated with CH2Cl2. The resulting
organic layer was washed with 10% NaOH solution, dried with
Na2SO4, and the solvent was removed under reduced pressure. The
crude product was then purified by flash chromatography using
cyclohexane/ethyl acetate 70:30 as eluent. The desired compound
was obtained as an oil. Yield: 98.4%.
1H NMR (400MHz, CDCl3) d: 7.54 (d, J¼ 15.6 Hz, 1H, CH]CH);
6.70 (s, 2H, CH arom.); 6.30 (d, J¼ 15.6 Hz, 1H, CH]CH); 4.17e4.12
(m, 1H, OCHH); 4.10e4.05 (m, 1H, OCHH); 3.82 (s, 6H, OCH3); 3.81
(s, 3H, OCH3); 3.46e3.38 (m, 2H, CH2Br); 2.22e2.17 (m, 1H, CH);
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13C APT NMR (CDCl3) d: 166.61 (C]O); 153.40 (C); 145.04 (CH]
CH); 140.19 (C); 129.74 (C); 116.89 (CH]CH); 105.28 (CH arom.);
66.99 (CH2); 60.88 (OCH3); 56.12 (OCH3); 36.92 (CH2); 34.77 (CH);
15.75 (CH3) ppm.
6.1.2. (R) (E)-3-Bromo-2-methylpropyl 3-(3,4,5-trimethoxyphenyl)
acrylate (R)-13
Following the same procedure described for compound (S)-13,
starting from (R)-3-bromo-2-(methyl)propan-1-ol, compound (R)-
13 was obtained as an oil. Yield: 95.9%.
1H NMR (400MHz, CDCl3) d: 7.60 (d, J¼ 16.0 Hz, 1H, CH]CH);
6.75 (s, 2H, CH arom.); 6.34 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.24e4.19
(m, 1H, OCHH); 4.16e4.011 (m, 1H, OCHH); 3.89 (s, 6H, OCH3); 3.88
(s, 3H, OCH3); 3.55e3.42 (m, 2H, CH2Br); 2.35e2.23 (m, 1H, CH);
1.11 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 166.72 (C]O); 153.46 (C); 145.12 (CH]
CH); 129.78 (C); 116.94 (CH]CH); 105.31 (CH arom.); 66.60 (CH2);
60.98 (OCH3); 56.19 (OCH3); 36.90 (CH2); 34.82 (CH); 15.80 (CH3)
ppm.
6.1.3. (S)-3-Bromo-2-methylpropyl 3,4,5-trimethoxybenzoate (S)-
14
A solution of 416mg (1.96mmol) of 3,4,5-trimethoxybenzoic
acid in 15mL of anhydrous CH2Cl2 was cooled at 0 C and 0.14mL
of (S)-3-bromo-2-(methyl)propan-1-ol (1.31mmol), 128mg
(1.05mmol) of 4-dimethylaminopiridine (DMAP) and 452mg
(2.36mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (EDCI) were added in this order. The reaction
mixturewas stirred at 0 C for 1 h and at room temperature for 18 h
and treated with CH2Cl2. The organic layer was washed three times
with water and twice with a saturated solution of NaHCO3. After
drying with Na2SO4, the solvent was removed under reduced
pressure. The crude product was then purified by flash chroma-
tography using cyclohexane/ethyl acetate 80:20 as eluent, yielding
426.4mg (94%) of the desired compound as an oil.
1H NMR (400MHz, CDCl3) d: 7.28 (s, 2H, CH arom.); 4.33e4.23
(m, 2H, OCH2); 3.89 (s, 9H, OCH3); 3.40 (d, J¼ 6.4 Hz, 2H, CH2Br);
2.38e2.32 (m, 1H, CH); 1.03 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.4. (R)-3-Bromo-2-methylpropyl 3,4,5-trimethoxybenzoate (R)-
14
Following the same procedure described for compound (S)-14,
starting from (R)-3-bromo-2-(methyl)propan-1-ol, compound (R)-
14 was obtained as an oil. Yield: 98%.
1H NMR (400MHz, CDCl3) d: 7.17 (s, 2H, CH arom.); 4.20e4.11
(m, 2H, OCH2); 3.78 (s, 9H, OCH3); 3.37 (d, J¼ 5.6 Hz, 2H, CH2Br);
2.26e2.18 (m, 1H, CH); 1.02 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.5. (S)-3-Bromo-2-methylpropyl anthracene-9-carboxylate (S)-
15
Following the same procedure described for compound (S)-13,
starting from anthracene-9-carboxylic acid and (S)-3-bromo-2-
(methyl)propan-1-ol, compound (S)-15 was obtained as an oil.
Yield: 97%.
1H NMR (CDCl3) d: 8.51 (s, 1H, CH arom.); 8.07e8.01 (m, 4H, CH
arom.); 7.58e7.48 (m, 4H, CH arom.); 4.65e4.56 (m, 2H, OCH2);
3.55e3.46 (m, 2H, CH2Br); 2.42e2.38 (m,1H, CH); 1.18 (d, J¼ 6.8 Hz,
3H, CH3) ppm.
6.1.6. (R)-3-Bromo-2-methylpropyl anthracene-9-carboxylate (R)-
15
Following the same procedure described for compound (S)-13,
starting from anthracene-9-carboxylic acid and (R)-3-bromo-2-
(methyl)propan-1-ol, compound (R)-15 was obtained as an oil.Yield: 99%.
1H NMR (400MHz, CDCl3) d: 8.53 (s, 1H, CH. arom.); 8.07e8.02
(m, 4H, CH arom.); 7.58e7.48 (m, 4H, CH arom.); 4.65e4.56 (m, 2H,
OCH2); 3.55e3.46 (m, 2H, CH2Br); 2.44e2.36 (m, 1H, CH); 1.18 (d,
J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.7. (S) (E)-3-Iodo-2-methylpropyl 3-(3,4,5-trimethoxyphenyl)
acrylate (S)-16
To a solution of 719.4mg (1.93mmol)) of compound (S)-13 in
8ml of acetone, NaI (1.16 g, 7.70mmol) was added and the resulting
mixture was maintained at reflux in the dark for 18 h. The reaction
mixture was cooled to room temperature, and the solvent was
removed under reduced pressure; the residue was dissolved in
CH2Cl2 and washed three times with water. The organic layer was
dried with Na2SO4, and the solvent was removed under reduced
pressure yielding 721.4mg (89%) of the desired compound (S)-16 as
a solid which was used as such for the next reaction. Mp: 81e84 C.
1H NMR (400MHz, CDCl3) d: 7.59 (d, J¼ 16.0 Hz, 1H, CH]CH);
6.75 (s, 2H, CH arom.); 6.34 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.19e4.14
(m, 1H, OCHH); 4.10e4.02 (m, 1H, OCHH); 3.88 (s, 6H, OCH3); 3.87
(s, 3H, OCH3); 3.33e3.22 (m, 2H, CH2I); 1.99e1.88 (m, 1H, CH); 1.07
(d, J¼ 6.4 Hz, 3H, CH3) ppm.
6.1.8. (R) (E)-3-Iodo-2-methylpropyl 3-(3,4,5-trimethoxyphenyl)
acrylate (R)-16
Following the same procedure described for compound (S)-16,
starting from 625.6mg (1.60mmol) of (R)-13, compound (R)-16
was obtained as an oil. Yield: 93%.
1H NMR (400MHz, CDCl3) d: 7.55 (d, J¼ 16.0 Hz, 1H, CH]CH);
6.71 (s, 2H, CH arom.); 6.30 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.16e4.07
(m, 1H, OCHH); 4.05e3.97 (m, 1H, OCHH); 3.84 (s, 6H, OCH3); 3.83
(s, 3H, OCH3); 3.31e3.18 (m, 2H, CH2I); 1.95e1.85 (m, 1H, CH); 1.03
(d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.9. (S)-3-Iodo-2-methylpropyl 3,4,5-trimethoxybenzoate (S)-17
Following the same procedure described for compound (S)-16,
starting from 214.1mg (0.62mmol) of (S)-14, compound (S)-17was
obtained as an oil. Yield: 99%.
1H NMR (400MHz, CDCl3) d: 7.27 (s, 2H, CH arom.); 4.25 (dd,
J¼ 11.2 Hz, J¼ 5.6 Hz,1H, OCHH); 4.16 (dd, J¼ 11.2 Hz, J¼ 7.2 Hz,1H,
OCHH); 3.88 (s, 9H, OCH3); 3.31e3.23 (m, 2H, CH2I); 2.05e1.98 (m,
1H, CH); 1.08 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.10. (R)-3-Iodo-2-methylpropyl 3,4,5-trimethoxybenzoate (R)-17
Following the same procedure described for compound (S)-16,
starting from 112.2mg (0.32mmol) of (R)-14, compound (R)-17
was obtained as an oil. Yield: 98%.
1H NMR (400MHz, CDCl3) d: 7.16 (s, 2H, CH arom.); 4.14 (dd,
J¼ 11.2 Hz, J¼ 5.6 Hz, 1H, OCHH); 4.05 (dd, J¼ 11.2 Hz, J¼ 5.6 Hz,
1H, OCHH); 3.78 (s, 9H, OCH3); 3.20e3.12 (m, 2H, CH2I); 1.96e1.86
(m, 1H, CH); 0.97 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.11. (S)-3-Iodo-2-methylpropyl anthracene-9-carboxylate (S)-18
Following the same procedure described for compound (S)-16,
starting from 208.6mg (0.54mmol) of (S)-15, compound (S)-18was
obtained as an oil. Yield: 99%.
1H NMR (400MHz, CDCl3) d: 8.52 (s, 1H, CH arom.); 8.09e8.01
(m, 4H, CH arom.); 7.59e7.48 (m, 4H, CH arom.); 4.61e4.59 (m, 1H,
OCHH); 4.47e4.46 (m, 1H, OCHH); 3.32e3.29 (m, 2H, CH2I);
2.07e1.99 (m, 1H, CH); 1.14 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.12. (R)-3-Iodo-2-methylpropyl anthracene-9-carboxylate (R)-18
Following the same procedure described for compound (S)-16,
starting from112.7mg (0.32mmol) of (R)-15, compound (R)-18was
obtained as an oil. Yield: 96%.
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(m, 4H, CH arom.); 7.62e7.48 (m, 4H, CH arom.); 4.58 (dd,
J¼ 11.2 Hz, J¼ 5.2 Hz, 1H, OCHH); 4.48 (dd, J¼ 11.2 Hz, J¼ 7.2 Hz,
1H, OCHH); 3.34e3.23 (m, 2H, CH2I); 2.08e2.00 (m,1H, CH); 1.16 (d,
J¼ 7.2 Hz, 3H, CH3) ppm.
6.1.13. General procedure for the synthesis of the (S) and (R)
enantiomers of the hydroxyaminoesters 19e27
The appropriate haloester ((S) and (R)-16, (S) and (R)-17, (S) and
(R)-18) (1mmol), K2CO3 (1mmol) and the suitable amino-
alkylalcohol (3-aminopropan-1-ol, 5-aminopentan-1-ol or 7-
aminoheptan-1-ol [43]) (2mmol) were dissolved in 1mL of anhy-
drous CH3CN. The mixture was heated at 80 C for 5e10 h. The re-
action mixture was cooled to room temperature, treated with
CH2Cl2 and the organic layer was washed with 10% NaOH solution.
After drying with Na2SO4, the solvent was removed under reduced
pressure and the residue purified by flash chromatography,
yielding a pale-yellow oil.
6.1.13.1. (R) (E)-3-((3-hydroxypropyl)amino)-2-methylpropyl 3-
(3,4,5-trimethoxyphenyl)acrylate (R)-19. Starting from (S)-16 and 3-
aminopropan-1-ol, compound (R)-19 was obtained as an oil. Yield:
50%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH 95:5:0.1.
1H NMR (400MHz, CDCl3) d: 7.54 (d, J¼ 16.0 Hz, 1H, CH]CH);
6.72 (s, 2H, CH arom.); 6.30 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.12e4.03
(m, 2H, OCH2); 3.84 (s, 6H, OCH3); 3.82 (s, 3H, OCH3); 3.75 (t,
J¼ 5.6 Hz, 2H, OCH2); 3.30e3.11 (bs, 2H, OH and NH); 2.83 (t,
J¼ 6.0 Hz, 2H, NCH2); 2.68e2.59 (m, 1H, NCHH); 2.53e2.45 (m, 1H,
NCHH); 2.05e1.97 (m, 1H, CH); 1.71e1.60 (m, 2H, CH2); 0.97 (d,
J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.13.2. (S) (E)-3-((3-hydroxypropyl)amino)-2-methylpropyl 3-
(3,4,5-trimethoxyphenyl)acrylate (S)-19. Starting from (R)-16 and 3-
aminopropan-1-ol, compound (S)-19 was obtained as an oil. Yield:
28%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH 95:5:0.1.
ESI-MS: 368.3[MþH]þ.
1H NMR (400MHz, CDCl3) d: 7.59 (d, 1H, J¼ 16.0 Hz, CH]CH);
6.76 (s, 2H, CH arom.); 6.34 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.18e4.05
(m, 2H, OCH2); 3.93e3.85 (m, 9H, OCH3); 3.81 (t, J¼ 5.2 Hz, 2H,
OCH2); 3.08 (bs, 2H, OH and NH); 2.90 (t, J¼ 5.6 Hz, 2H, NCH2);
2.72e2.67 (m, 1H, NCHH); 2.58e2.53 (m, 1H, NCHH); 2.15e2.06 (m,
1H, CH); 1.77e1.68 (m, 2H, CH2); 1.02 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.13.3. (R)-3-((3-hydroxypropyl)amino)-2-methylpropyl 3,4,5-
trimethoxybenzoate (R)-20. Starting from (S)-17 and 3-
aminopropan-1-ol, compound (R)-20 was obtained as an oil.
Yield: 53%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH
95:5:0.1.
1H NMR (400MHz, CDCl3) d: 7.28 (s, 2H, CH arom.); 4.22 (d,
J¼ 6.0 Hz, 2H, OCH2); 3.89 (s, 9H, OCH3); 3.79 (t, J¼ 5.2 Hz, 2H,
OCH2); 2.88e2.85 (m, 2H, NCH2); 2.68 (dd, J¼ 11.8 Hz, J¼ 6.4 Hz,
1H, NCHH); 2.56 (dd, J¼ 11.8 Hz, J¼ 6.8 Hz, 1H, NCHH); 2.15e2.10
(m, 1H, CH); 1.65e1.62 (m, 2H, CH2); 1.04 (d, J¼ 6.8 Hz, 3H, CH3)
ppm.
6.1.13.4. (S)-3-((3-hydroxypropyl)amino)-2-methylpropyl 3,4,5-
trimethoxybenzoate (S)-20. Starting from (R)-17 and 3-
aminopropan-1-ol, compound (S)-20 was obtained as an oil.
Yield: 68%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH
95:5:0.1.
1H NMR (400MHz, CDCl3) d: 7.20 (s, 2H, CH arom.); 4.15 (d,
J¼ 6.0 Hz, 2H, OCH2); 3.81 (s, 9H, OCH3); 3.70 (t, J¼ 5.6 Hz, 2H,
OCH2); 3.01 (s, 2H, NH and OH); 2.78 (t, J¼ 5.6 Hz, 2H, NCH2); 2.61
(dd, J¼ 12.0 Hz, J¼ 6.8 Hz, 1H, NCHH); 2.48 (dd, J¼ 12.0 Hz,
J¼ 6.8 Hz, 1H, NCHH); 2.09e2.01 (m, 1H, CH); 1.64e1.58 (m, 2H,CH2); 0.96 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.13.5. (R)-3-((3-hydroxypropyl)amino)-2-methylpropyl anthra-
cene-9-carboxylate (R)-21. Starting from (S)-18 and 3-
aminopropan-1-ol, compound (R)-21 was obtained as an oil.
Yield: 77%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH
95:5:0.1.
1H NMR (400MHz, CDCl3) d: 8.50 (s, 1H, CH arom.); 8.04e7.98
(m, 4H, CH arom.); 7.56e7.45 (m, 4H, CH arom.); 4.52 (d, J¼ 6.0 Hz,
2H, OCH2); 3.57 (t, J¼ 5.2 Hz, 2H, OCH2); 3.05 (s, 2H, NH and OH);
2.81 (t, J¼ 5.6 Hz, 2H, NCH2); 2.72 (dd, J¼ 11.6 Hz, J¼ 6.0 Hz, 1H,
NCHH); 2.56 (dd, J¼ 11.6 Hz, J¼ 6.8 Hz, 1H, NCHH); 2.22e2.14 (m,
1H, CH); 1.64e1.60 (m, 2H, CH2); 1.07 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.13.6. (S)-3-((3-hydroxypropyl)amino)-2-methylpropyl anthra-
cene-9-carboxylate (S)-21. Starting from (R)-18 and 3-
aminopropan-1-ol, compound (S)-21 was obtained as an oil.
Yield: 29%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH
95:5:0.1.
1H NMR (400MHz, CDCl3) d: 8.48 (s, 1H, CH arom.); 8.03e7.97
(m, 4H, CH arom.); 7.53e7.44 (m, 4H, CH arom); 4.50 (d, J¼ 6.0 Hz,
2H, OCH2); 3.75 (t, J¼ 5.6 Hz, 2H, OCH2); 2.92 (s, 2H, NH and OH);
2.80 (t, J¼ 5.6 Hz, 2H, NCH2); 2.71 (dd, J¼ 11.6 Hz, J¼ 6.4 Hz, 1H,
NCHH); 2.56 (dd, J¼ 11.6 Hz, J¼ 6.8 Hz, 1H, NCHH); 2.22e2.14 (m,
1H, CH); 1.64e1.61 (m, 2H, CH2); 1.06 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.13.7. (R) (E)-3-((5-hydroxypentyl)amino)-2-methylpropyl 3-
(3,4,5-trimethoxyphenyl)acrylate (R)-22. Starting from (S)-16 and 5-
aminopentan-1-ol, compound (R)-22 was obtained as an oil. Yield:
47%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH 95:6:0.8.
1H NMR (400MHz, CDCl3) d: 7.56 (d, J¼ 16.0 Hz, 1H, CH]CH);
6.73 (s, 2H, CH arom.); 6.32 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.11 (d,
J¼ 5.6 Hz, 2H, OCH2); 3.86 (s, 6H, OCH3); 3.85 (s, 3H, OCH3); 3.59 (t,
J¼ 6.8 Hz, 2H, OCH2); 2.68e2.51 (m, 3H, NCH2 and NCHH);
2.51e2.42 (m,1H, NCHH); 2.11e2.01 (m,1H, CH); 2.00e1.88 (bs, 2H,
OH and NH); 1.60e1.45 (m, 4H, CH2); 1.43e1.32 (m, 2H, CH2); 0.99
(d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.13.8. (S) (E)-3-((5-hydroxypentyl)amino)-2-methylpropyl 3-
(3,4,5-trimethoxyphenyl)acrylate (S)-22. Starting from (R)-16 and 5-
aminopentan-1-ol, compound (S)-22 was obtained as an oil. Yield:
46%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH 95:6:0.8.
1H NMR (400MHz, CDCl3) d: 7.58 (d, J¼ 16.0 Hz, 1H, CH]CH);
6.75 (s, 2H, CH arom.); 6.33 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.14 (d,
J¼ 6.0 Hz, 2H, OCH2); 3.88 (s, 6H, OCH3); 3.87 (s, 3H, OCH3); 3.63 (t,
J¼ 6.4 Hz, 2H, OCH2); 2.67e2.53 (m, 3H, NCH2 and NCHH);
2.52e2.44 (m, 1H, NCHH); 2.41e2.30 (bs, 2H, OH and NH);
2.09e2.00 (m, 1H, CH); 1.59e1.42 (m, 4H, CH2); 1.41e1.32 (m, 2H,
CH2); 0.98 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
13C APT NMR (100MHz, CDCl3) d: 167.08 (C]O); 153.40 (C);
144.87 (CH]CH); 140.13 (C); 129.84 (C); 117.17 (CH]CH); 105.28
(CH arom.); 67.47 (CH2); 62.28 (CH2); 60.93 (OCH3); 56.16 (OCH3);
52.92 (CH2); 49.80 (CH2); 33.10 (CH); 32.35 (CH2); 29.40 (CH2);
23.39 (CH2); 15.50 (CH3) ppm.
6.1.13.9. (R)-3-((5-hydroxypentyl)amino)-2-methylpropyl 3,4,5-
trimethoxybenzoate (R)-23. Starting from (S)-17 and 5-
aminopentan-1-ol, compound (R)-23 was obtained as an oil.
Yield: 63%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH
95:5:0.5.
1H NMR (400MHz, CDCl3) d: 7.28 (s, 2H, CH arom.); 4.29e4.20
(m, 2H, OCH2); 3.89 (s, 9H, OCH3); 3.61 (t, J¼ 6.4 Hz, 2H, OCH2);
2.67 (dd, J¼ 12.0 Hz, J¼ 6.8 Hz, 1H, NCHH); 2.62 (t, J¼ 7.2 Hz, 2H,
CH2); 2.55 (dd, J¼ 12.0 Hz, J¼ 6.8 Hz, 1H, NCHH); 2.17e2.12 (m, 1H,
CH); 1.84 (s, 2H, NH and OH); 1.59e1.48 (m, 4H, CH2); 1.43e1.39 (m,
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6.1.13.10. (S)-3-((5-hydroxypentyl)amino)-2-methylpropyl 3,4,5-
trimethoxybenzoate (S)-23. Starting from (R)-17 and 5-
aminopentan-1-ol, compound (S)-23 was obtained as an oil.
Yield: 57%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH
95:5:0.5.
1H NMR (400MHz, CDCl3) d: 7.19 (s, 2H, CH arom.); 4.15 (dd,
J¼ 6.0 Hz, J¼ 2.0 Hz, 2H, OCH2); 3.80 (s, 9H, OCH3); 3.49 (t,
J¼ 6.4 Hz, 2H, OCH2); 2.58 (dd, J¼ 12.0 Hz, J¼ 6.8 Hz 1H, NCHH);
2.51 (t, J¼ 7.2 Hz, 2H, NCH2); 2.45 (dd, J¼ 12.0 Hz, J¼ 6.8 Hz, 1H,
NCHH); 2.24 (s, 2H, NH and OH); 2.10e2.02 (m, 1H, CH); 1.49e1.38
(m, 4H, CH2); 1.33e1.27 (m, 2H, CH2); 0.95 (d, J¼ 6.8 Hz, 3H, CH3)
ppm.
6.1.13.11. (R)-3-((5-hydroxypentyl)amino)-2-methylpropyl anthra-
cene-9-carboxylate (R)-24. Starting from (S)-18 and 5-
aminopentan-1-ol, compound (R)-24 was obtained as an oil.
Yield: 50%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH
95:6:0.8.
1H NMR (400MHz, CDCl3) d: 8.50 (s, 1H, CH arom.); 8.04e7.99
(m, 4H, CH arom.); 7.55e7.45 (m, 4H, CH arom.); 4.55 (d, J¼ 6.4 Hz,
2H, OCH2); 3.54 (t, J¼ 6.4 Hz, 2H, OCH2); 2.73e2.55 (m, 4H, NCH2);
2.45e2.17 (m, 1H, CH); 1.85 (s, 2H, NH and OH); 1.52e1.39 (m, 4H,
CH2); 1.34e1.27 (m, 2H, CH2); 1.07 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.13.12. (S)-3-((5-hydroxypentyl)amino)-2-methylpropyl anthra-
cene-9-carboxylate (S)-24. Starting from (R)-18 and 5-
aminopentan-1-ol, compound (S)-24 was obtained as an oil.
Yield: 44%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH
95:6:0.8.
1H NMR (400MHz, CDCl3) d: 8.52 (s, 1H, CH arom.); 8.05e8.00
(m, 4H, CH arom.); 7.55e7.46 (m, 4H, CH arom.); 4.56 (d, J¼ 6.0 Hz,
2H, OCH2); 3.57 (t, J¼ 6.4 Hz, 2H, OCH2); 2.75e2.57 (m, 4H, NCH2);
2.26e2.19 (m, 1H, CH); 1.79 (s, 2H, NH and OH); 1.55e1.42 (m, 4H,
CH2); 1.37e1.30 (m, 2H, CH2); 1.08 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.13.13. (R) (E)-3-((7-hydroxyheptyl)amino)-2-methylpropyl 3-
(3,4,5-trimethoxyphenyl)acrylate (R)-25. Starting from (S)-16 and 7-
aminoheptan-1-ol [43], compound (R)-25 was obtained as an oil.
Yield: 50%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH
95:5:0.5.
1H NMR (400MHz, CDCl3) d: 7.58 (d, J¼ 15.6 Hz, 1H, CH]CH);
6.75 (s, 2H, CH arom.); 6.34 (d, J¼ 15.6 Hz, 1H, CH]CH); 4.14 (d,
J¼ 6.0 Hz, 2H, OCH2); 3.90 (s, 6H, OCH3); 3.88 (s, 3H, OCH3); 3.61 (t,
J¼ 6.6 Hz, 2H, OCH2); 2.68e2.50 (m, 4H, NCH2); 2.10e2.06 (m, 1H,
CH); 1.76 (s, 2H, NH and OH); 1.54e1.50 (m, 4H, CH2); 1.45e1.26 (m,
6H, CH2); 1.01 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.13.14. (S) (E)-3-((7-hydroxyheptyl)amino)-2-methylpropyl 3-
(3,4,5-trimethoxyphenyl)acrylate (S)-25. Starting from (R)-16 and
7-aminoheptan-1-ol [43], compound (S)-25 was obtained as an oil.
Yield: 25%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH
95:5:0.5.
1H NMR (400MHz, CDCl3) d: 7.58 (d, J¼ 16.0 Hz, 1H, CH]CH);
6.74 (s, 2H, CH arom.); 6.33 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.14 (dd,
J¼ 6.0 Hz, J¼ 2.4 Hz, 2H, OCH2); 3.86 (s, 6H, OCH3); 3.85 (s, 3H,
OCH3); 3.60 (t, J¼ 6.6 Hz, 2H, OCH2); 2.65 (dd, J¼ 12.0 Hz,
J¼ 6.8 Hz, 1H, NCHH); 2.58 (t, J¼ 7.2 Hz, 2H, NCH2); 2.51 (dd,
J¼ 12.0 Hz, J¼ 6.8 Hz, 1H, NCHH); 2.11e2.03 (m, 1H, CH); 1.68 (s,
2H, NH and OH); 1.55e1.46 (m, 4H, CH2); 1.44e1.27 (m, 6H, CH2);
1.01 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.13.15. (R)-3-((7-hydroxyheptyl)amino)-2-methylpropyl 3,4,5-
trimethoxybenzoate (R)-26. Starting from (S)-17 and 7-aminoheptan-1-ol [43], compound (R)-26 was obtained as an oil.
Yield: 41%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH
95:5:0.5.
1H NMR (400MHz, CDCl3) d: 7.21 (s, 2H, CH arom.); 4.19 (d,
J¼ 6.0 Hz, 2H, OCH2); 3.82 (s, 9H, OCH3); 3.50 (t, J¼ 6.4 Hz, 2H,
OCH2); 3.44 (s, 2H, NH and OH); 2.70 (dd, J¼ 12.4 Hz, J¼ 6.8 Hz, 1H,
NCHH); 2.64e2.55 (m, 3H, NCH2 and NCHH); 2.26e2.18 (m, 1H,
CH); 1.51e1.42 (m, 4H, CH2); 1.32e1.18 (m, 6H, CH2); 1.02 (d,
J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.13.16. (S)-3-((7-hydroxyheptyl)amino)-2-methylpropyl 3,4,5-
trimethoxybenzoate (S)-26. Starting from (R)-17 and 7-
aminoheptan-1-ol [43], compound (S)-26 was obtained as an oil.
Yield: 50%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH
90:10:1.
1H NMR (400MHz, CDCl3) d: 7.22 (s, 2H, CH arom.); 4.18 (d,
J¼ 6.0 Hz, 2H, OCH2); 3.83 (s, 9H, OCH3); 3.53 (t, J¼ 6.4 Hz, 2H,
OCH2); 2.62 (dd, J¼ 12.0 Hz, J¼ 6.8 Hz, 1H, NCHH); 2.54e2.46 (m,
3H, NCH2 and NCHH); 2.12e2.09 (m, 3H, CH, NH and OH);
1.48e1.40 (m, 4H, CH2); 1.34e1.20 (m, 6H, CH2); 0.98 (d, J¼ 6.8 Hz,
3H, CH3) ppm.
6.1.13.17. (R)-3-((7-hydroxyheptyl)amino)-2-methylpropyl anthra-
cene-9-carboxylate (R)-27. Starting from (S)-18 and 7-
aminoheptan-1-ol [43], compound (R)-27 was obtained as an oil.
Yield: 45%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH
95:5:0.5.
1H NMR (400MHz, CDCl3) d: 8.47 (s, 1H, CH arom.); 8.01e7.96
(m, 4H, CH arom.); 7.51e7.42 (m, 4H, CH arom.); 4.52 (d, J¼ 5.6 Hz,
2H, OCH2); 3.52 (t, J¼ 6.4 Hz, 2H, OCH2); 2.68 (dd, J¼ 12.0 Hz,
6.8 Hz, 1H, NCHH); 2.57e2.51 (m, 3H, NCH2 and NCHH); 2.23e2.17
(m,1H, CH); 1.46e1.38 (m, 4H, CH2); 1.28e1.15 (m, 6H, CH2); 1.04 (d,
J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.13.18. (S)-3-((7-hydroxyheptyl)amino)-2-methylpropyl anthra-
cene-9-carboxylate (S)-27. Starting from (R)-18 and 7-
aminoheptan-1-ol [43], compound (S)-27 was obtained as an oil.
Yield: 56%. Chromatographic eluent: CH2Cl2/CH3OH/NH4OH
95:5:0.5.
1H NMR (400MHz, CDCl3) d: 8.46 (s, 1H, CH arom.); 8.02e7.95
(m, 4H, CH arom.); 7.51e7.42 (m, 4H, CH arom.); 4.52 (d, J¼ 6.0 Hz,
2H, OCH2); 3.53 (t, J¼ 6.4 Hz, 2H, OCH2); 2.68 (dd, J¼ 11.6 Hz,
J¼ 6.8 Hz, 1H, NCHH); 2.56e2.50 (m, 3H, NCH2 and NCHH);
2.22e2.15 (m, 1H, CH); 1.97 (s, 2H, NH and OH); 1.48e1.36 (m, 4H,
CH2); 1.27e1.15 (m, 6H, CH2); 1.04 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.14. General procedure for the synthesis of the (S) and (R)
enantiomers of the (hydroxyalkyl) methylaminoesters 28e36
A 1mmol portion of the appropriate hydroxyaminoester ((R)
and (S) 19e27) was dissolved in 5mL of anhydrous ethanol and
HCOOH (17mmol) and 37% HCHO solution (5mmol) were added.
The mixture was heated to 80 C for 4e5 h and concentrated in
vacuo. The residue was then dissolved in CH2Cl2 and the organic
layer was washed with 10% NaOH solution. After drying with
Na2SO4, the solvent was removed under reduced pressure and the
residue purified by flash chromatography, yielding a yellow oil.
6.1.14.1. (R)-3-((3-hydroxypropyl)(methyl)amino)-2-methylpropyl
(E)-3-(3,4,5-trimethoxyphenyl) acrylate (R)-28. From (R)-19. Chro-
matographic eluent: CH2Cl2/CH3OH/NH4OH 95:5:0.5. Yield: 64%.
1H NMR (400MHz, CDCl3) d: 7.57 (d, J¼ 15.6 Hz, 1H, CH]CH);
6.73 (s, 2H, CH arom.); 6.33 (d, J¼ 15.6 Hz, 1H, CH]CH); 4.20e4.13
(m, 1H, OCHH); 4.08e3.98 (m, 1H, OCHH); 3.86 (s, 6H, OCH3); 3.85
(s, 3H, OCH3); 3.77 (t, J¼ 5.2 Hz, 2H, OCH2); 2.61 (t, J¼ 5.6 Hz, 2H,
NCH2); 2.44e2.35 (m, 1H, NCHH); 2.34e2.25 (m, 1H, NCHH); 2.29
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(d, J¼ 6.8 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 166.94 (C]O); 153.43 (C); 144.87 (CH]
CH); 140.19 (C); 129.87 (C); 117.18 (CH]CH); 105.33 (CH arom.);
67.80 (CH2); 63.88 (CH2); 62.05 (CH2); 60.92 (OCH3); 58.54 (CH2);
56.17 (OCH3); 42.08 (NCH3); 30.97 (CH); 27.85 (CH2); 15.65 (CH3)
ppm.
6.1.14.2. (S)-3-((3-hydroxypropyl)(methyl)amino)-2-methylpropyl
(E)-3-(3,4,5-trimethoxyphenyl) acrylate (S)-28. From (S)-19. Chro-
matographic eluent: CH2Cl2/CH3OH/NH4OH 95:5:0.5. Yield: 79%.
1H NMR (400MHz, CDCl3) d: 7.60 (d, J¼ 16.0 Hz, 1H, CH]CH);
6.76 (s, 2H, CH arom.); 6.35 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.22e4.16
(m, 1H, OCHH); 4.10e4.02 (m, 1H, OCHH); 3.89 (s, 6H, OCH3); 3.87
(s, 3H, OCH3); 3.81 (t, J¼ 5.2 Hz 2H, OCH2); 2.73e2.65 (m, 2H,
NCH2); 2.51e2.44 (m,1H, NCHH); 2.43e2.36 (m,1H, NCHH); 2.35 (s,
3H, NCH3); 2.26e2.14 (m, 1H, CH); 1.81e1.70 (m, 2H, CH2); 1.06 (d,
J¼ 6.4 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 166.95 (C]O); 153.43 (C); 144.87 (CH]
CH); 140.16 (C); 129.88 (C); 117.19 (CH]CH); 105.30 (CH arom.);
67.84 (CH2); 64.03 (CH2); 62.08 (CH2); 60.95 (OCH3); 58.70 (CH2);
56.17 (OCH3); 42.12 (NCH3); 30.99 (CH); 27.84 (CH2); 15.70 (CH3)
ppm.
6.1.14.3. (R)-3-((3-hydroxypropyl)(methyl)amino)-2-methylpropyl
3,4,5-trimethoxybenzoate (R)-29. From (R)-20. Chromatographic
eluent: CH2Cl2/CH3OH/NH4OH 95:5:0.5. Yield: 82%.
1H NMR (400MHz, CDCl3) d: 7.28 (s, 2H, CH arom.); 4.28 (dd,
J¼ 10.8 Hz, J¼ 5.2 Hz, 1H, OCHH); 4.13 (dd, J¼ 10.8 Hz, J¼ 6.0 Hz
1H, OCHH); 3.88 (s, 9H, OCH3); 3.77 (t, J¼ 5.2 Hz, 2H, OCH2); 2.57 (t,
J¼ 5.2 Hz, 2H, NCH2); 2.39e2.35 (m, 1H, NCHH); 2.28e2.16 (m, 2H,
NCHH and CH); 2.24 (s, 3H, NCH3); 1.71e1.67 (m, 2H, CH2); 1.02 (d,
J¼ 6.4 Hz, 3H, CH3) ppm.
6.1.14.4. (S)-3-((3-hydroxypropyl)(methyl)amino)-2-methylpropyl
3,4,5-trimethoxybenzoate (S)-29. From (S)-20. Chromatographic
eluent: CH2Cl2/CH3OH/NH4OH 95:5:0.5. Yield: 84%.
1H NMR (400MHz, CDCl3) d: 7.23 (s, 2H, CH arom.); 4.23 (dd,
J¼ 10.8 Hz, J¼ 5.2 Hz, 1H, OCHH); 4.07 (dd, J¼ 10.8 Hz, J¼ 6.4 Hz,
1H, OCHH); 3.83 (s, 9H, OCH3); 3.71 (t, J¼ 5.2 Hz, 2H, CH2); 2.52 (t,
J¼ 5.6 Hz, 2H, CH2); 2.32 (dd, J¼ 12.0 Hz, J¼ 6.4 Hz, 1H, NCHH);
2.23e2.11 (m, 2H, NCHH and CH); 2.19 (s, 3H, NCH3); 1.65e1.62 (m,
2H, CH2); 0.97 (d, J¼ 6.4 Hz, 3H, CH3) ppm.
6.1.14.5. (R)-3-((3-hydroxypropyl)(methyl)amino)-2-methylpropyl
anthracene-9-carboxylate (R)-30. From (R)-21. Chromatographic
eluent: CH2Cl2/CH3OH/NH4OH 90:10:1. Yield: 98%.
1H NMR (400MHz, CDCl3) d: 8.52 (s, 1H, CH arom.); 8.06e8.01
(m, 4H, CH arom.); 7.56e7.47 (m, 4H, CH arom.); 4.61 (dd,
J¼ 10.8 Hz, J¼ 6.8 Hz, 1H, OCHH); 4.48 (dd, J¼ 10.8 Hz, J¼ 5.2 Hz,
1H, OCHH); 3.80 (t, J¼ 5.2 Hz, 2H, OCH2); 2.58 (t, J¼ 5.2 Hz, 2H,
NCH2); 2.46e2.42 (m, 1H, CH); 2.35e2.26 (m, 2H, NCH2); 2.27 (s,
3H, NCH3); 1.72e1.68 (m, 2H, CH2); 1.10 (d, J¼ 5.6 Hz 3H, CH3) ppm.
6.1.14.6. (S)-3-((3-hydroxypropyl)(methyl)amino)-2-methylpropyl
anthracene-9-carboxylate (S)-30. From (S)-21. Chromatographic
eluent: CH2Cl2/CH3OH/NH4OH 90:10:1. Yield: 92%.
1H NMR (400MHz, CDCl3) d: 8.48 (s, 1H, CH arom.); 8.00 (m, 4H,
CH arom.); 7.52e7.43 (m, 4H, CH arom.); 4.58 (dd, J¼ 10.8 Hz,
J¼ 4.8 Hz 1H, OCHH); 4.45 (dd, J¼ 10.8 Hz, J¼ 5.6 Hz, 1H, OCHH);
3.77 (t, J¼ 5.2 Hz, 2H, OCH2); 2.53 (t, J¼ 6.0 Hz, 2H, NCH2); 2.32 (dd,
J¼ 15.2 Hz, J¼ 10.0 Hz, 1H, NCHH); 2.26e2.23 (m, 2H, NCHH and
CH); 2.23 (s, 3H, NCH3); 1.69e1.63 (m, 2H, CH2); 1.07 (d, J¼ 6.0 Hz,
3H, CH3) ppm.6.1.14.7. (R)-3-((5-hydroxypentyl)(methyl)amino)-2-methylpropyl
(E)-3-(3,4,5-trimethoxyphenyl) acrylate (R)-31. From (R)-22. Chro-
matographic eluent: CH2Cl2/CH3OH/NH4OH 90:10:1. Yield: 93%.
1H NMR (400MHz, CDCl3) d: 7.57 (d, J¼ 15.6 Hz 1H, CH]CH);
6.74 (s, H, 2CH arom.); 6.33 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.28e4.21
(m, 1H, OCHH); 4.06e3.98 (m, 1H, OCHH); 3.87 (s, 6H, OCH3); 3.86
(s, 3H, OCH3); 3.61 (t, J¼ 6.4 Hz, 2H, OCH2); 2.36e2.26 (m, 3H, NCH2
and NCHH); 2.18 (s, 3H, NCH3); 2.17e2.10 (m,1H, NCHH); 2.09e2.01
(m,1H, CH); 1.98 (bs,1H, OH); 1.60e1.52 (m, 2H, CH2); 1.51e1.41 (m,
2H, CH2); 1.41e1.32 (m, 2H, CH2); 0.98 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 167.16 (C]O); 153.43 (C); 144.62 (CH]
CH); 139.81 (C); 129.94 (C); 117.44 (CH]CH); 105.27 (CH arom.);
68.18 (CH2); 62.83 (CH2); 61.32 (CH2); 60.95 (OCH3); 58.10 (CH2);
56.18 (OCH3); 42.74 (NCH3); 32.55 (CH2); 31.27 (CH); 26.99 (CH2);
23.47 (CH2); 15.91 (CH3) ppm.
6.1.14.8. (S)-3-((5-hydroxypentyl)(methyl)amino)-2-methylpropyl
(E)-3-(3,4,5-trimethoxyphenyl) acrylate (S)-31. From (S)-22. Chro-
matographic eluent: CH2Cl2/CH3OH/NH4OH 90:10:1. Yield: 94%.
1H NMR (400MHz, CDCl3) d: 7.58 (d, J¼ 15.6 Hz, 1H, CH]CH);
6.74 (s, 2H, CH arom.); 6.34 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.28e4.19
(m, 1H, OCHH); 4.07e3.98 (m, 1H, OCHH); 3.87 (s, 6H, OCH3); 3.86
(s, 3H, OCH3); 3.61 (t, J¼ 6.4 Hz, 2H, OCH2); 2.37e2.25 (m, 3H, NCH2
and NCHH); 2.19 (s, 3H, NCH3); 2.18e2.11 (m, 1H, NCHH); 2.10e2.01
(m, 1H, CH); 1.60e1.50 (m, 2H, CH2); 1.50e1.42 (m, 2H, CH2);
1.41e1.32 (m, 2H, CH2); 0.99 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
6.1.14.9. (R)-3-((5-hydroxypentyl)(methyl)amino)-2-methylpropyl
3,4,5-trimethoxybenzoate (R)-32. From (R)-23. Chromatographic
eluent: CH2Cl2/CH3OH/NH4OH 90:10:1. Yield: 84%.
1H NMR (400MHz, CDCl3) d: 7.28 (s, 2H, CH arom.); 4.33 (dd,
J¼ 10.8 Hz, J¼ 4.4 Hz, 1H, OCHH); 4.11 (dd, J¼ 10.8 Hz, J¼ 6.4 Hz,
1H, OCHH); 3.88 (s, 9H, OCH3); 3.59 (t, J¼ 6.4 Hz, 2H, OCH2);
2.32e2.22 (m, 3H, NCH2 and NCHH); 2.18 (s, 3H, NCH3); 2.16e2.11
(m, 2H, NCHH and CH); 1.54e1.41 (m, 4H, CH2); 1.38e1.34 (m, 2H,
CH2); 1.00 (d, J¼ 6.0 Hz, 3H, CH3) ppm.
6.1.14.10. (S)-3-((5-hydroxypentyl)(methyl)amino)-2-methylpropyl
3,4,5-trimethoxybenzoate (S)-32. From (S)-23. Chromatographic
eluent: CH2Cl2/CH3OH/NH4OH 90:10:1. Yield: 88%.
1H NMR (400MHz, CDCl3) d: 7.23 (s, 2H, CH arom.); 4.28 (dd,
J¼ 10.8 Hz, J¼ 4.8 Hz, 1H, OCHH); 4.06 (dd, J¼ 10.8 Hz, J¼ 6.4 Hz,
1H, OCHH); 3.83 (s, 9H, OCH3); 3.53 (t, J¼ 6.4 Hz, 2H, OCH2); 2.46 (s,
1H, OH); 2.31e2.25 (m, 3H, NCH2 and NCHH); 2.14 (s, 3H, NCH3);
2.13e2.05 (m, 2H, NCHH and CH); 1.51e1.37 (m, 4H, CH2); 1.33e1.27
(m, 2H, CH2); 0.96 (d, J¼ 6.4 Hz, 3H, CH3) ppm.
6.1.14.11. (R)-3-((5-hydroxypentyl)(methyl)amino)-2-methylpropyl
anthracene-9-carboxylate (R)-33. From (R)-24. Chromatographic
eluent: CH2Cl2/CH3OH 90:10. Yield: 99%.
1H NMR (400MHz, CDCl3) d: 8.51 (s, 1H, CH arom.); 8.07e8.00
(m, 4H, CH arom.); 7.55e7.46 (m, 4H, CH arom.); 4.66 (dd,
J¼ 10.8 Hz, J¼ 4.4 Hz, 1H, OCHH), 4.48 (dd, J¼ 10.8 Hz, J¼ 6.4 Hz,
1H, OCHH); 3.59 (t, J¼ 6.4 Hz, 2H, OCH2); 2.41e2.30 (m, 3H, NCH2
and NCHH); 2.23 (s, 3H, NCH3); 2.20e2.16 (m, 2H, NCHH and CH);
1.56e1.43 (m, 4H, CH2); 1.39e1.33 (m, 2H, CH2); 1.06 (d, J¼ 6.4 Hz,
3H, CH3) ppm.
6.1.14.12. (S)-3-((5-hydroxypentyl)(methyl)amino)-2-methylpropyl
anthracene-9-carboxylate (S)-33. From (S)-24. Chromatographic
eluent: CH2Cl2/CH3OH 90:10. Yield: 95%.
1H NMR (400MHz, CDCl3) d: 8.51 (s, 1H, CH arom.); 8.07e8.00
(m, 4H, CH arom.); 7.55e7.46 (m, 4H, CH arom.); 4.66 (dd,
J¼ 10.8 Hz, J¼ 4.4 Hz, 1H, OCHH), 4.48 (dd, J¼ 10.8 Hz, J¼ 6.0 Hz,
1H, OCHH); 3.59 (t, J¼ 6.4 Hz, 2H, OCH2); 2.42e2.25 (m, 3H, NCH2
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1.57e1.44 (m, 4H, CH2); 1.39e1.33 (m, 2H, CH2); 1.06 (d, J¼ 6.4 Hz,
3H, CH3) ppm.
6.1.14.13. (R)-3-((7-hydroxyheptyl)(methyl)amino)-2-methylpropyl
(E)-3-(3,4,5-trimethoxyphenyl) acrylate (R)-34. From (R)-25. Chro-
matographic eluent: CH2Cl2/CH3OH/NH4OH 90:10:1. Yield: 89%.
1H NMR (400MHz, CDCl3) d: 7.58 (d, J¼ 16.0 Hz, 1H, CH]CH);
6.73 (s, 2H, CH arom.); 6.34 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.12 (m,
2H, OCH2); 3.88 (s, 6H, OCH3); 3.86 (s, 3H, OCH3); 3.61 (t, J¼ 6.6 Hz,
2H, OCH2); 2.32e2.27 (m, 3H, NCH2 and NCHH); 2.18 (s, 3H, NCH3);
2.19e2.00 (m, 2H, NCHH and CH); 1.53 (s, 2H, NH and OH);
1.45e1.36 (m, 4H, CH2); 1.34e1.18 (m, 6H, CH2); 0.98 (d, J¼ 6.4 Hz,
3H, CH3) ppm.
6.1.14.14. (S)-3-((7-hydroxyheptyl)(methyl)amino)-2-methylpropyl
(E)-3-(3,4,5-trimethoxyphenyl) acrylate (S)-34. From (S)-25. Chro-
matographic eluent: CH2Cl2/CH3OH/NH4OH 90:10:1. Yield: 97%.
1H NMR (400MHz, CDCl3) d: 7.58 (d, J¼ 16.0 Hz, 1H, CH]CH);
6.73 (s, 2H, CH arom.); 6.34 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.12 (m,
2H, OCH2), 3.87 (s, 6H, OCH3); 3.85 (s, 3H, OCH3); 3.61 (t, J¼ 6.6 Hz,
2H, OCH2); 2.32e2.27 (m, 3H, NCH2 and NCHH); 2.18 (s, 3H, NCH3);
2.19e2.00 (m, 2H, NCHH and CH); 1.55e1.51 (m, 2H, CH2);
1.50e1.40 (m, 2H, CH2); 1.28e1.15 (m, 6H, CH2); 0.98 (d, J¼ 6.4 Hz,
3H, CH3) ppm.
6.1.14.15. (R)-3-((7-hydroxyheptyl)(methyl)amino)-2-methylpropyl
3,4,5-trimethoxybenzoate (R)-35. From (R)-26. Chromatographic
eluent: CH2Cl2/CH3OH/NH4OH 90:10:1. Yield: 91%.
1H NMR (400MHz, CDCl3) d: 7.21 (s, 2H, CH arom.); 4.25 (dd,
J¼ 10.4 Hz, J¼ 4.4 Hz, 1H, OCHH); 4.04 (dd, J¼ 10.8 Hz, J¼ 6.4 Hz,
1H, OCHH); 3.81 (s, 9H, OCH3); 3.50 (t, J¼ 6.8 Hz, 2H, OCH2);
2.29e2.19 (m, 4H, NCHH, CH2 and OH); 2.14e2.03 (m, 2H, NCHH
and CH); 2.11 (s, 3H, NCH3); 1.45e1.34 (m, 4H, CH2); 1.26e1.12 (m,
6H, CH2); 0.93 (d, J¼ 6.4 Hz, 3H, CH3) ppm.
6.1.14.16. (S)-3-((7-hydroxyheptyl)(methyl)amino)-2-methylpropyl
3,4,5-trimethoxybenzoate (S)-35. From (S)-26. Chromatographic
eluent: CH2Cl2/CH3OH/NH4OH 90:10:1. Yield: 97%.
1H NMR (400MHz, CDCl3) d: 7.24 (s, 2H, CH arom.); 4.29 (dd,
J¼ 10.8 Hz, 4.4 Hz, 1H, OCHH); 4.07 (dd, J¼ 10.8 Hz, J¼ 6.4 Hz, 1H,
OCHH); 3.84 (s, 9H, OCH3); 3.55 (t, J¼ 6.8 Hz, 2H, OCH2); 2.32e2.23
(m, 3H, NCHH and CH2); 2.17e2.06 (m, 2H, NCHH and CH); 2.15 (s,
3H, NCH3); 1.50e1.38 (m, 4H, CH2); 1.28e1.15 (m, 6H, CH2); 0.97 (d,
J¼ 6.4 Hz, 3H, CH3) ppm.
6.1.14.17. (R)-3-((7-hydroxyheptyl)(methyl)amino)-2-methylpropyl
anthracene-9-carboxylate (R)-36. From (R)-27. Chromatographic
eluent: CH2Cl2/CH3OH/NH4OH 93:7:0.3. Yield: 90%.
1H NMR (400MHz, CDCl3) d: 8.48 (s, 1H, CH arom.); 8.04e7.97
(m, 4H, CH arom.); 7.52e7.43 (m, 4H, CH arom.); 4.61 (dd,
J¼ 10.4 Hz, J¼ 4.0 Hz, 1H, OCHH); 4.46 (dd, J¼ 10.8 Hz, J¼ 6.4 Hz,
1H, OCHH); 3.57 (t, J¼ 6.8 Hz, 2H, OCH2); 2.38e2.27 (m, 3H, NCHH
and CH2); 2.19 (s, 3H, NCH3); 2.19e2.13 (m, 2H, NCHH and CH);
1.50e1.42 (m, 4H, CH2); 1.34e1.20 (m, 6H, CH2); 1.04 (d, J¼ 6.4 Hz,
3H, CH3) ppm.
6.1.14.18. (S)-3-((7-hydroxyheptyl)(methyl)amino)-2-methylpropyl
anthracene-9-carboxylate (S)-36. From (S)-27. Chromatographic
eluent: CH2Cl2/CH3OH/NH4OH 90:10:1. Yield: 92%.
1H NMR (400MHz, CDCl3) d: 8.47 (s, 1H, CH arom.); 8.05e7.96
(m, 4H, CH arom.); 7.52e7.43 (m, 4H, CH arom.); 4.63 (dd,
J¼ 10.8 Hz, J¼ 4.4 Hz, 1H, OCHH); 4.46 (dd, J¼ 10.8 Hz, J¼ 6.4 Hz,
1H, OCHH); 3.56 (t, J¼ 6.8 Hz, 2H, OCH2); 2.37e2.27 (m, 3H, NCHH
and CH2); 2.19 (s, 3H, NCH3); 2.19e2.14 (m, 2H, NCHH and CH); 1.95(s, 1H, OH); 1.50e1.41 (m, 4H, CH2); 1.32e1.18 (m, 6H, CH2); 1.04 (d,
J¼ 6.0 Hz, 3H, CH3) ppm.
6.1.15. General procedures for the synthesis of the (S) and (R)
enantiomers of the diesters 1e12
Diester compounds were synthesized using two different gen-
eral procedures:
6.1.15.1. General procedure A. A solution of the suitable (hydrox-
yalkyl)methylaminoester (0.250mmol) in 5mL of an. CH2Cl2 was
cooled at 0 C and 0.360mmol of the appropriate carboxylic acid
((E)-3-(3,4,5-trimethoxyphenyl)acrylic acid or 3,4,5-
trimethoxybenzoic acid), 0.083mmol of 4-dimethylaminopiridine
(DMAP) and 0.500mmol of 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDCl) were added. The reaction
mixture was stirred for 1 h at 0 C and 48 h at room temperature.
Then CH2Cl2 was added and the organic layer was washed twice
with a saturated solution of NaHCO3. After drying with Na2SO4, the
solution was concentrated to dryness and the crude product was
purified by flash chromatography with the eluting systems
described below. The pure compounds were transformed into the
corresponding white solid hydrochloride salts that were crystal-
lized from abs. ethanol/petroleum ether.
6.1.15.2. General procedure B. A 0.250mmol portion of the appro-
priate carboxylic acid ((E)-3-(3,4,5-trimethoxyphenyl)acrylic acid
or anthracene-9-carboxylic acid) was transformed into the acyl
chloride by reaction with SOCl2 (2 eq) in 3mL of CHCl3 (free of
ethanol) at 60 C for 4e5 h.
After cooling to room temperature, the solution was concen-
trated to dryness; the mixture was washed twice with cyclohexane
and then organic layer was removed by a rotary evaporation. The
acyl chloride obtained was dissolved in CHCl3 (free of ethanol), and
the appropriate (hydroxyalkyl)methylaminoester (1 eq) was added.
The mixture was heated to 60 C for 4 h, cooled to room tempera-
ture and then CH2Cl2 was added. The organic phase was washed
with 10% NaOH solution, dried with Na2SO4 and then concentrated
to dryness. The crude products obtained were purified by flash
chromatography with the eluting systems described below, and the
desired compounds were obtained as oil.
All the compounds were transformed into the corresponding
hydrochloride as white solid. The salts were crystallized from abs.
ethanol/petroleum ether.
6.1.15.3. (R) (E)-3-(methyl(2-methyl-3-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)propyl)amino) propyl 3,4,5-trimethoxybenzoate (R)-1.
Procedure A, starting from (R)-28 and 3,4,5-trimethoxybenzoic
acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH/NH4OH
98:2:0.2. Yield: 74%.
1H NMR (400MHz, CDCl3) d: 7.56 (d, J¼ 16.0 Hz, 1H, CH]CH);
7.26 (s, 2H, CH arom.); 6.72 (s, 2H, CH arom.); 6.31 (d, J¼ 16.0 Hz,
1H, CH]CH); 4.36 (t, J¼ 6.4 Hz, 2H, OCH2); 4.22 (dd, J¼ 10.8 Hz,
J¼ 5.2 Hz, 1H, OCHH); 4.03 (dd, J¼ 10.8 Hz, J¼ 6.4 Hz, 1H, OCHH);
3.86 (s, 9H, OCH3); 3.85 (s, 6H, OCH3); 3.84 (s, 3H, OCH3); 2.63e2.50
(m, 2H, NCH2); 2.49e2.38 (m, 1H, NCHH); 2.30 (s, 3H, NCH3);
2.29e2.20 (m,1H, NCHH); 2.18e2.03 (m,1H, CH); 2.02e1.90 (m, 2H,
CH2); 1.01 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 167.00 (C]O); 166.16 (C]O); 153.41 (C);
152.89 (C); 144.61 (CH]CH); 142.15 (C); 140.09 (C); 129.90 (C);
125.42(C); 117.34 (CH]CH); 106.78 (CH arom.); 105.24 (CH arom.);
67.96 (CH2); 63.47 (CH2); 61.34 (CH2); 60.92 (OCH3); 60.85 (OCH3);
56.19 (OCH3); 56.14 (OCH3); 54.59 (CH2); 42.64 (NCH3); 31.34 (CH);
26.76 (CH2); 15.79 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
E. Teodori et al. / European Journal of Medicinal Chemistry 182 (2019) 11165518C30H42NO10¼ 576.2803, found 576.2797.
Hydrochloride: mp 50e55 C.
6.1.15.4. (S) (E)-3-(methyl(2-methyl-3-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)propyl)amino) propyl 3,4,5-trimethoxybenzoate (S)-1.
Procedure A, starting from (S)-28 and 3,4,5-trimethoxybenzoic
acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH/NH4OH
98:2:0.2. Yield: 61%.
1H NMR (400MHz, CDCl3) d: 7.55 (d, J¼ 16.0 Hz, 1H, CH]CH);
7.25 (s, 2H, CH arom.); 6.72 (s, 2H, CH arom.); 6.31 (d, J¼ 16.0 Hz,
1H, CH]CH); 4.34 (t, J¼ 6.8 Hz, 2H, OCH2); 4.22 (dd, J¼ 10.8 Hz,
J¼ 4.8 Hz, 1H, OCHH); 4.00 (dd, J¼ 10.8 Hz, J¼ 6.8 Hz, 1H, OCHH);
3.86 (s, 9H, OCH3); 3.85 (s, 6H, OCH3); 3.84 (s, 3H, OCH3); 2.50e2.44
(m, 2H, NCH2); 2.33 (dd, J¼ 12.0 Hz, J¼ 7.6 Hz, 1H, NCHH); 2.22 (s,
3H, NCH3); 2.19e2.14 (m, 1H, NCHH); 2.10e2.01 (m, 1H, CH);
1.93e1.86 (m, 2H, CH2); 0.97 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 166.96 (C]O); 166.17 (C]O); 153.42
(C); 152.91 (C); 144.79 (CH]CH); 142.22 (C); 140.14 (C); 129.85 (C);
125.28 (C); 117.18 (CH]CH); 106.81 (CH arom.); 105.26 (CH arom.);
67.79 (CH2); 63.25 (CH2); 61.10 (CH2); 60.93 (OCH3); 60.87 (OCH3);
56.22 (OCH3); 56.15 (OCH3); 54.55 (CH2); 42.44 (NCH3); 31.12 (CH);
26.39 (CH2); 15.89 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C30H42NO10¼ 576.2803, found 576.2804.
Hydrochloride: mp 46e50 C.
6.1.15.5. (R) (E)-3-(methyl(2-methyl-3-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)propyl)amino) propyl anthracene-9-carboxylate (R)-2.
Procedure B, starting from (R)-28 and anthracene-9-carboxylic
acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH/NH4OH
98:2:0.2. Yield: 37%.
1H NMR (400MHz, CDCl3) d: 8.50 (s, 1H, CH arom.); 8.04e7.99
(m, 4H, CH arom.); 7.56 (d, J¼ 16.0 Hz, 1H, CH]CH); 7.53e7.45 (m,
4H, CH arom.); 6.69 (s, 2H, CH arom.); 6.32 (d, J¼ 16.0 Hz, 1H, CH]
CH); 4.69 (t, J¼ 6.4 Hz, 2H, OCH2); 4.25 (dd, J¼ 10.8 Hz, J¼ 4.8 Hz,
1H, OCHH); 4.08 (dd, J¼ 10.8 Hz, J¼ 6.0 Hz, 1H, OCHH); 3.86 (s, 3H,
OCH3); 3.82 (s, 6H, OCH3); 2.72e2.58 (m, 2H, NCH2); 2.50e2.40 (m,
1H, NCHH); 2.31 (s, 3H, NCH3); 2.30e2.22 (m, 1H, NCHH);
2.20e2.03 (m, 3H, CH2 and CH); 1.04 (d, J¼ 6.4 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 169.69 (C]O); 167.10 (C]O); 153.37 (C);
144.65 (CH]CH); 142.65 (C); 130.98 (C); 129.92 (C); 129.23 (CH
arom.); 128.61 (CH arom.); 128.38 (C); 128.08 (C); 126.93 (CH
arom.); 125.46 (CH arom.); 125.00 (CH arom.); 117.38 (CH]CH);
105.21 (CH arom.); 67.86 (CH2); 64.16 (CH2); 61.25 (CH2); 60.95
(OCH3); 56.11 (OCH3); 54.78 (CH2); 42.57 (NCH3); 31.30 (CH); 26.75
(CH2); 15.83 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C35H40NO7¼ 586.2799, found 586.2791.
Hydrochloride: mp 87e92 C.
6.1.15.6. (S) (E)-3-(methyl(2-methyl-3-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)propyl)amino) propyl anthracene-9-carboxylate (S)-2.
Procedure B, starting from (S)-28 and anthracene-9-carboxylic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH/NH4OH
98:2:0.2. Yield: 32%.
1H NMR (400MHz, CDCl3) d: 8.50 (s, 1H, CH arom.); 8.03 (d,
J¼ 8.8 Hz, 2H, CH arom.); 8.00 (d, J¼ 8.8 Hz, 2H, CH arom.); 7.56 (d,
J¼ 16.0 Hz, 1H, CH]CH); 7.53e7.45 (m, 4H, CH arom.); 6.69 (s, 2H,
CH arom.); 6.33 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.69 (t, J¼ 6.4 Hz, 2H,
OCH2); 4.26 (dd, J¼ 10.8 Hz, J¼ 4.8 Hz, 1H, OCHH); 4.08 (dd,
J¼ 10.8 Hz, J¼ 6.0 Hz, 1H, OCHH); 3.86 (s, 3H, OCH3); 3.82 (s, 6H,
OCH3); 2.56 (t, J¼ 6.8 Hz, 2H, NCH2); 2.41 (dd, J¼ 12.4 Hz, J¼ 7.6 Hz,
1H, NCHH); 2.27 (s, 3H, NCH3); 2.22 (dd, J¼ 12.4 Hz, J¼ 7.2 Hz, 1H,NCHH); 2.12e2.02 (m, 3H, NCH2 and CH); 1.02 (d, J¼ 6.8 Hz, 3H,
CH3) ppm.
13C APT NMR (CDCl3) d: 169.59 (C]O); 167.01 (C]O); 153.38
(C); 144.88 (CH]CH); 142.55 (C); 130.96 (C); 129.84 (C); 129.33 (CH
arom.); 128.64 (CH arom.); 128.38 (C); 128.25 (C); 127.00 (CH
arom.); 125.49 (CH arom.); 124.93 (CH arom.); 117.15 (CH]CH);
105.24 (CH arom.); 67.61 (CH2); 63.86 (CH2); 60.96 (OCH3); 60.92
(CH2); 56.12 (OCH3); 54.72 (CH2); 42.30 (NCH3); 30.99 (CH); 26.22
(CH2); 15.94 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C35H40NO7¼ 586.2799, found 586.2792.
Hydrochloride: mp 80e82 C.
6.1.15.7. (R) (E)-2-methyl-3-(methyl(3-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)propyl)amino) propyl 3,4,5-trimethoxybenzoate (R)-3.
Procedure A, starting from (R)-29 and ((E)-3-(3,4,5-
trimethoxyphenyl)acrylic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH 96:4. Yield:
86%.
1H NMR (400MHz, CDCl3) d: 7.57 (d, J¼ 16.0 Hz, 1H, CH]CH);
7.28 (s, 2H, CH arom.); 6.74 (s, 2H, CH arom.); 6.32 (d, J¼ 16.0 Hz,
1H, CH]CH); 4.36 (dd, J¼ 10.4 Hz, J¼ 4.8 Hz, 1H, OCHH); 4.25 (t,
J¼ 6.4 Hz, 2H, OCH2); 4.14 (dd, J¼ 10.4 Hz, J¼ 6.4 Hz, 1H, OCHH);
3.88 (s, 9H, OCH3); 3.87 (s, 9H, OCH3); 2.58e2.35 (m, 3H, NCHH and
NCH2); 2.25 (s, 3H, NCH3); 2.24e2.10 (m, 2H, NCHH and CH);
1.90e1.80 (m, 2H, CH2); 1.03 (d, J¼ 6.0 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 166.96 (C]O); 166.22 (C]O); 153.43
(C); 152.93 (C); 144.70 (CH]CH); 129.90 (C); 125.47 (C); 117.32
(CH]CH); 106.78 (CH arom.); 105.23 (CH arom.); 68.44 (CH2);
62.87 (CH2); 61.32 (CH2); 60.97 (OCH3); 60.91 (OCH3); 56.21
(OCH3); 56.16 (OCH3); 54.74 (CH2); 42.66 (NCH3); 31.41 (CH); 26.73
(CH2); 15.90 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C30H42NO10¼ 576.2803, found 576.2802.
Hydrochloride: mp 49e53 C.
6.1.15.8. (S) (E)-2-methyl-3-(methyl(3-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)propyl)amino) propyl 3,4,5-trimethoxybenzoate (S)-3.
Procedure A, starting from (S)-29 and ((E)-3-(3,4,5-
trimethoxyphenyl)acrylic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH 96:4. Yield:
81%.
1H NMR (400MHz, CDCl3) d: 7.54 (d, J¼ 16.0 Hz, 1H, CH]CH);
7.25 (s, 2H, CH arom.); 6.71 (s, 2H, CH arom.); 6.28 (d, J¼ 16.0 Hz,
1H, CH]CH); 4.32 (dd, J¼ 10.8 Hz, J¼ 4.8 Hz, 1H, OCHH); 4.22 (t,
J¼ 6.8 Hz, 2H, OCH2); 4.11 (dd, J¼ 10.8 Hz, J¼ 6.4 Hz, 1H, OCHH);
3.85 (s, 9H, OCH3); 3.84 (s, 6H, OCH3); 3.83 (s, 3H, OCH3); 2.44 (t,
J¼ 6.8 Hz, 2H, NCH2); 2.35 (dd, J¼ 11.6 Hz, J¼ 7.2 Hz, 1H, NCHH);
2.21 (s, 3H, NCH3); 2.19e2.10 (m, 2H, NCHH and CH); 1.86e1.79 (m,
2H, CH2); 0.99 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 166.91 (C]O); 166.19 (C]O); 153.45
(C); 152.94 (C); 144.65 (CH]CH); 140.22 (C); 129.91 (C); 125.49 (C);
117.35 (CH]CH); 106.88 (CH arom.); 105.34 (CH arom.); 68.43
(CH2); 62.87 (CH2); 61.37 (CH2); 60.92 (OCH3); 60.86 (OCH3); 56.21
(OCH3); 56.17 (OCH3); 54.76 (CH2); 42.66 (NCH3); 31.47 (CH); 26.78
(CH2); 15.86 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C30H42NO10¼ 576.2803, found 576.2805.
Hydrochloride: mp 50e55 C.
6.1.15.9. (R) (E)-2-methyl-3-(methyl(3-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)propyl)amino) propyl anthracene-9-carboxylate (R)-4.
Procedure A, starting from (R)-30 and ((E)-3-(3,4,5-
trimethoxyphenyl)acrylic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH 98:2. Yield:
E. Teodori et al. / European Journal of Medicinal Chemistry 182 (2019) 111655 1967%.
1H NMR (400MHz, CDCl3) d: 8.49 (s, 1H, CH arom.); 8.04 (d,
J¼ 8.8 Hz, 2H, CH arom.); 8.00 (d, J¼ 8.8 Hz, 2H, CH arom.); 7.56 (d,
J¼ 16.0 Hz, 1H, CH]CH); 7.52e7.44 (m, 4H, CH arom.); 6.68 (s, 2H,
CH arom.); 6.31 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.66 (dd, J¼ 10.8 Hz,
J¼ 4.0 Hz, 1H, OCHH); 4.50 (dd, J¼ 10.8 Hz, J¼ 5.6 Hz, 1H, OCHH);
4.27 (t, J¼ 6.0 Hz, 2H, OCH2); 3.86 (s, 3H, OCH3); 3.81 (s, 6H, OCH3);
2.60e2.39 (m, 3H, NCHH and NCH2); 2.28 (s, 3H, NCH3); 2.27e2.17
(m, 2H, NCHH and CH); 1.98e1.82 (m, 2H, CH2); 1.09 (d, J¼ 6.4 Hz,
3H, CH3) ppm.
13C APT NMR (CDCl3) d: 169.75 (C]O); 167.01 (C]O); 153.37
(C); 144.74 (CH]CH); 140.32 (C); 130.99 (C); 129.81 (C); 129.20
(CH]CH); 128.60 (CH arom); 128.41 (C); 126.90 (CH arom); 125.46
(CH arom); 125.06 (CH arom); 117.29 (CH]CH); 105.26 (CH arom.);
69.12 (CH2); 62.64 (CH2), 61.18 (CH2); 60.93 (OCH3); 56.10 (OCH3);
54.49 (CH2); 42.60 (NCH3); 31.21 (CH); 26.65 (CH2); 16.04 (CH3)
ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C35H40NO7¼ 586.2799, found 586.2793.
Hydrochloride: mp 96e99 C.
6.1.15.10. (S) (E)-2-methyl-3-(methyl(3-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)propyl)amino) propyl anthracene-9-carboxylate (S)-4.
Procedure A, starting from (R)-30 and ((E)-3-(3,4,5-
trimethoxyphenyl)acrylic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH 98:2. Yield:
70%.
1H NMR (400MHz, CDCl3) d: 8.46 (s, 1H, CH arom.); 8.02 (d,
J¼ 8.8 Hz, 2H, CH arom.); 7.97 (d, J¼ 8.8 Hz, 2H, CH arom.); 7.53 (d,
J¼ 16.0 Hz, 1H, CH]CH); 7.49e7.42 (m, 4H, CH arom.); 6.65 (s, 2H,
CH arom.); 6.29 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.63 (dd, J¼ 10.8 Hz,
J¼ 4.0 Hz, 1H, OCHH); 4.46 (dd, J¼ 10.8 Hz, J¼ 6.0 Hz, 1H, OCHH);
4.25 (t, J¼ 6.4 Hz, 2H, OCH2); 3.83 (s, 3H, OCH3); 3.78 (s, 6H, OCH3);
2.51e2.40 (m, 3H, NCHH and NCH2); 2.23 (s, 3H, NCH3); 2.23e2.18
(m, 2H, NCHH and CH); 1.88e1.81 (m, 2H, CH2); 1.04 (d, J¼ 6.4 Hz,
3H, CH3) ppm.
13C APT NMR (CDCl3) d: 169.87 (C]O); 167.01 (C]O); 153.34
(C); 144.69 (CH]CH); 141.85 (C); 130.97 (C); 129.89 (C); 129.18 (CH
arom.); 128.60 (CH arom.); 128.38 (C); 126.89 (CH arom.); 125.46
(CH arom.); 125.08 (CH arom.); 117.36 (CH]CH); 105.14 (CH
arom.); 69.27 (CH2); 62.78 (CH2); 61.31 (CH2); 60.96 (OCH3); 56.16
(OCH3); 56.07 (OCH3); 54.59 (CH2); 42.62 (NCH3); 31.28 (CH); 26.68
(CH2); 16.00 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C35H40NO7¼ 586.2799, found 586.2792.
Hydrochloride: mp 88e92 C.
6.1.15.11. (R) (E)-5-(methyl(2-methyl-3-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)propyl)amino) pentyl 3,4,5-trimethoxybenzoate (R)-5.
Procedure A, starting from (R)-31 and 3,4,5-trimethoxybenzoic
acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH/NH4OH
98:2:0.2. Yield: 70.5%.
1H NMR (400MHz, CDCl3) d: 7.58 (d, J¼ 16.0 Hz, 1H, CH]CH);
7.28 (s, 2H, CH arom.); 6.74 (s, 2H, CH arom.); 6.34 (d, J¼ 16.0 Hz,
1H, CH]CH); 4.30 (t, J¼ 6.8 Hz, 2H, OCH2); 4.24 (dd, J¼ 10.8 Hz,
J¼ 4.8 Hz, 1H, OCHH); 4.02 (dd, J¼ 10.8 Hz, J¼ 6.8 Hz, 1H, OCHH);
3.89 (s, 9H, OCH3); 3.88 (s, 6H, OCH3); 3.87 (s, 3H, OCH3); 2.37e2.30
(m, 3H, NCHH and NCH2); 2.21 (s, 3H, NCH3); 2.20e2.12 (m, 1H,
NCHH); 2.11e2.04 (m, 1H, CH); 1.82e1.72 (m, 2H, CH2); 1.59e1.40
(m, 4H, CH2); 0.99 (d, J¼ 6.4 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 167.04 (C]O); 166.25 (C]O); 153.45
(C); 152.93 (C); 144.62 (CH]CH); 142.23 (C); 140.17 (C); 129.93 (C);
125.49 (C); 117.40 (CH]CH); 106.86 (CH arom.); 105.30 (CH arom.);
68.09 (CH2); 65.16 (CH2); 61.30 (CH2); 60.95 (OCH3); 60.89 (OCH3);58.12 (CH2); 56.25 (OCH3); 56.18 (OCH3); 42.69 (NCH3); 31.28 (CH);
28.72 (CH2); 26.96 (CH2); 23.84 (CH2); 15.88 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C32H46NO10¼ 604.3116, found 604.3115.
Hydrochloride: mp 95e98 C.
6.1.15.12. (S) (E)-5-(methyl(2-methyl-3-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)propyl)amino) pentyl 3,4,5-trimethoxybenzoate (S)-5.
Procedure A, starting from (S)-31 and 3,4,5-trimethoxybenzoic
acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH/NH4OH
98:2:0.2. Yield: 28.5%.
1H NMR (400MHz, CDCl3) d: 7.57 (d, J¼ 16.0 Hz, 1H, CH]CH);
7.27 (s, 2H, CH arom.); 6.74 (s, 2H, CH arom.); 6.33 (d, J¼ 16.0 Hz,
1H, CH]CH); 4.29 (t, J¼ 6.4 Hz, 2H, OCH2); 4.23 (dd, J¼ 10.8 Hz,
J¼ 4.8 Hz, 1H, OCHH); 4.00 (dd, J¼ 10.8 Hz, J¼ 6.8 Hz, 1H, OCHH);
3.88 (s, 9H, OCH3); 3.87 (s, 6H, OCH3); 3.86 (s, 3H, OCH3); 2.38e2.27
(m, 3H, NCHH and NCH2); 2.19 (s, 3H, NCH3); 2.18e2.14 (m, 1H,
NCHH); 2.10e2.00 (m, 1H, CH); 1.80e1.72 (m, 2H, CH2); 1.54e1.40
(m, 4H, CH2); 0.98 (d, J¼ 6.4 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 167.05 (C]O); 166.24 (C]O); 153.43
(C); 152.91 (C); 144.58 (CH]CH); 142.17 (C); 140.12 (C); 129.93 (C);
125.50 (C); 117.43 (CH]CH); 106.82 (CH arom.); 105.25 (CH arom.);
68.12 (CH2); 65.18 (CH2); 61.34 (CH2); 60.94 (OCH3); 60.89 (OCH3);
58.14 (CH2); 56.23 (OCH3); 56.16 (OCH3); 42.73 (NCH3); 31.30 (CH);
28.72 (CH2); 27.05 (CH2); 23.84 (CH2); 15.86 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C32H46NO10¼ 604.3116, found 604.3125.
Hydrochloride: mp 90e95 C.
6.1.15.13. (R) (E)-5-(methyl(2-methyl-3-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)propyl)amino) pentyl anthracene-9-carboxylate (R)-6.
Procedure B, starting from (R)-31 and anthracene-9-carboxylic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH/NH4OH
98:2:0.2. Yield: 54%.
1H NMR (400MHz, CDCl3) d: 8.51 (s, 1H, CH arom.); 8.04e8.00
(m, 4H, CH arom.); 7.58 (d, J¼ 16.0 Hz, 1H, CH]CH); 7.55e7.45 (m,
4H, CH arom.); 6.73 (s, 2H, CH arom.); 6.34 (d, J¼ 16.0 Hz, 1H, CH]
CH); 4.61 (t, J¼ 6.4 Hz, 2H, OCH2); 4.23 (dd, J¼ 10.8 Hz, J¼ 4.8 Hz,
1H, OCHH); 4.03 (dd, J¼ 10.8 Hz, J¼ 6.4 Hz, 1H, OCHH); 3.87 (s, 3H,
OCH3); 3.85 (s, 6H, OCH3); 2.41e2.29 (m, 3H, NCHH and NCH2); 2.21
(s, 3H, NCH3); 2.20e2.11 (m, 1H, NCHH); 2.10e2.04 (m, 1H, CH);
1.94e1.87 (m, 2H, CH2); 1.59e1.46 (m, 4H, CH2); 0.99 (d, J¼ 6.4 Hz,
3H, CH3) ppm.
13C APT NMR (CDCl3) d: 169.73 (C]O); 167.06 (C]O); 153.42
(C); 144.64 (CH]CH); 131.00 (C); 129.93 (C); 129.22 (CH arom.);
128.61 (CH arom.); 128.38 (C); 126.92 (CH arom.); 125.46 (CH
arom.); 125.00 (CH arom.); 117.41 (CH]CH); 105.26 (CH arom.);
68.05 (CH2); 65.84 (CH2); 61.22 (CH2); 60.96 (OCH3); 58.03 (CH2);
56.16 (OCH3); 42.65 (NCH3); 31.25 (CH); 28.70 (CH2); 26.79 (CH2);
23.90 (CH2); 15.89 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C37H44NO7¼614.3112, found 614.3102.
Hydrochloride: mp 79e83 C.
6.1.15.14. (S) (E)-5-(methyl(2-methyl-3-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)propyl)amino) pentyl anthracene-9-carboxylate (S)-6.
Procedure B, starting from (S)-31 and anthracene-9-carboxylic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH/NH4OH
98:2:0.2. Yield: 71%.
ESI-MS: 614.2 [MþH]þ.
1H NMR (400MHz, CDCl3) d: 8.50 (s, 1H, CH arom.); 8.04e7.99
(m, 4H, CH arom.); 7.58 (d, J¼ 16.0 Hz, 1H, CH]CH); 7.55e7.45 (m,
4H, CH arom.); 6.73 (s, 2H, CH arom.); 6.34 (d, J¼ 16.0 Hz, 1H, CH]
CH); 4.62 (t, J¼ 6.8 Hz, 2H, OCH2); 4.24 (dd, J¼ 10.8 Hz, J¼ 4.8 Hz,
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OCH3); 3.85 (s, 6H, OCH3); 2.37e2.29 (m, 3H, NCHH and NCH2);
2.20 (s, 3H, NCH3); 2.18e2.13 (m,1H, NCHH); 2.11e2.04 (m,1H, CH);
1.94e1.86 (m, 2H, CH2); 1.59e1.46 (m, 4H, CH2); 0.98 (d, J¼ 6.4 Hz,
3H, CH3) ppm.
13C APT NMR (CDCl3) d: 169.73 (C]O); 167.07 (C]O); 153.42
(C); 144.59 (CH]CH); 131.00 (C); 129.95 (C); 129.21 (CH arom.);
128.61 (CH arom.); 128.38 (C); 128.16 (C); 126.91 (CH arom.);
125.45 (CH arom.); 125.01 (CH arom.); 117.46 (CH]CH); 105.24 (CH
arom.); 68.11 (CH2); 65.86 (CH2); 61.31 (CH2); 60.96 (OCH3); 58.09
(CH2); 56.15 (OCH3); 42.73 (NCH3); 31.32 (CH); 28.72 (CH2); 26.95
(CH2); 23.91 (CH2); 15.87 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C37H44NO7¼614.3112, found 614.3104.
Hydrochloride: mp 76e80 C.
6.1.15.15. (R) (E)-2-methyl-3-(methyl(5-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)pentyl)amino) propyl 3,4,5-trimethoxybenzoate (R)-7.
Procedure B, starting from (R)-32 and ((E)-3-(3,4,5-
trimethoxyphenyl)acrylic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH 96:4. Yield:
78%.
1H NMR (400MHz, CDCl3) d: 7.57 (d, J¼ 16.0 Hz, 1H, CH]CH);
7.28 (s, 2H, CH arom.); 6.74 (s, 2H, CH arom.); 6.33 (d, J¼ 16.0 Hz,
1H, CH]CH); 4.34 (dd, J¼ 10.8 Hz, J¼ 4.4 Hz, 1H, OCHH); 4.17 (t,
J¼ 6.4 Hz, 2H, OCH2); 4.13 (dd, J¼ 10.8 Hz, J¼ 6.4 Hz, 1H, OCHH);
3.88 (s, 9H, OCH3); 3.87 (s, 9H, OCH3); 2.36e2.31 (m, 3H, NCHH and
NCH2); 2.22 (s, 3H, NCH3); 2.21e2.10 (m, 2H, NCHH and CH);
1.71e1.65 (m, 2H, CH2); 1.56e1.35 (m, 4H, CH2); 1.02 (d, J¼ 6.4 Hz,
3H, CH3) ppm.
13C APT NMR (CDCl3) d: 167.04 (C]O); 166.27 (C]O); 153.89
(C); 152.94 (C); 144.61 (CH]CH); 142.19 (C); 129.93 (C); 125.48 (C);
117.42 (CH]CH); 106.81 (CH arom.); 105.24 (CH arom.); 68.49
(CH2); 64.55 (CH2); 60.96 (CH2); 60.90 (OCH3); 58.14 (CH2); 56.25
(OCH3); 56.23 (OCH3); 42.77 (NCH3); 31.31 (CH); 28.68 (CH2); 27.00
(CH2); 23.80 (CH2); 15.99 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C32H46NO10¼ 604.3116, found 604.3110.
Hydrochloride: mp 53e57 C.
6.1.15.16. (S) (E)-2-methyl-3-(methyl(5-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)pentyl)amino) propyl 3,4,5-trimethoxybenzoate (S)-7.
Procedure B, starting from (S)-32 and ((E)-3-(3,4,5-
trimethoxyphenyl)acrylic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH 96:4. Yield:
67%.
1H NMR (400MHz, CDCl3) d: 7.51 (d, J¼ 16.0 Hz, 1H, CH]CH);
7.22 (s, 2H, CH arom.); 6.68 (s, 2H, CH arom.); 6.27 (d, J¼ 16.0 Hz,
1H, CH]CH); 4.28 (dd, J¼ 10.8 Hz, J¼ 4.4 Hz,1H, OCHH); 4.12e4.05
(m, 3H, OCHH and OCH2); 3.82 (s, 9H, OCH3); 3.80 (s, 6H, OCH3);
3.79 (s, 3H, OCH3); 2.29e2.20 (m, 3H, NCHH and NCH2); 2.14 (s, 3H,
NCH3); 2.13e2.06 (m, 2H, NCHH and CH); 1.66e1.55 (m, 2H, CH2);
1.46e1.30 (m, 4H, CH2); 0.96 (d, J¼ 6.0 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 166.98 (C]O); 166.18 (C]O); 153.39
(C); 152.89 (C); 144.56 (CH]CH); 142.13 (C); 140.03 (C); 129.93 (C);
125.50 (C); 117.43 (CH]CH); 106.74 (CH arom.); 105.19 (CH arom.);
68.50 (CH2); 64.55 (CH2); 61.32 (CH2); 60.91 (OCH3); 60.86 (OCH3);
58.13 (CH2); 56.17 (OCH3); 56.11 (OCH3); 42.78 (NCH3); 31.33 (CH);
28.66 (CH2); 27.01 (CH2); 23.78 (CH2); 15.93 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C32H46NO10¼ 604.3116, found 604.3106.
Hydrochloride: mp 59e62 C.
6.1.15.17. (R) (E)-2-methyl-3-(methyl(5-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)pentyl)amino) propyl anthracene-9-carboxylate (R)-8.Procedure A, starting from (R)-33 and ((E)-3-(3,4,5-
trimethoxyphenyl)acrylic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH 97:3. Yield:
78%.
1H NMR (400MHz, CDCl3) d: 8.51 (s, 1H, CH arom.); 8.05 (d,
J¼ 8.8 Hz, 2H, CH arom.); 8.01 (d, J¼ 8.8 Hz, 2H, CH arom.); 7.58 (d,
J¼ 16.0 Hz, 1H, CH]CH); 7.54e7.45 (m, 4H, CH arom.); 6.72 (s, 2H,
CH arom.); 6.35 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.65 (dd, J¼ 10.4 Hz,
J¼ 4.0 Hz, 1H, OCHH); 4.49 (dd, J¼ 10.4 Hz, J¼ 6.0 Hz, 1H, OCHH);
4.19 (t, J¼ 6.4 Hz, 2H, OCH2); 3.86 (s, 3H, OCH3); 3.84 (s, 6H, OCH3);
2.43e2.30 (m, 3H, NCHH and NCH2); 2.23 (s, 3H, NCH3); 2.22e2.17
(m, 2H, NCHH and CH); 1.72e1.65 (m, 2H, CH2); 1.53e1.42 (m, 4H,
CH2); 1.06 (d, J¼ 6.4 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 169.83 (C]O); 167.10 (C]O); 153.37 (C);
144.63 (CH]CH); 139.95 (C); 131.00 (C); 129.92 (C); 129.20 (CH
arom); 128.63 (CH arom); 128.38 (C); 126.86 (CH arom); 125.42 (CH
arom); 125.15 (CH arom); 117.47 (CH]CH); 105.13 (CH arom); 69.33
(CH2); 64.61 (CH2); 61.28 (CH2); 60.98 (OCH3); 58.13 (CH2); 56.13
(OCH3); 42.72 (NCH3); 31.22 (CH); 28.73 (CH2); 27.00 (CH2); 23.83
(CH2); 16.10 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C37H44NO7¼614.3112, found 614.3115.
Hydrochloride: mp 129e132 C.
6.1.15.18. (S) (E)-2-methyl-3-(methyl(5-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)pentyl)amino) propyl anthracene-9-carboxylate (S)-8.
Procedure A, starting from (S)-33 and ((E)-3-(3,4,5-
trimethoxyphenyl)acrylic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH 97:3. Yield:
72%.
1H NMR (400MHz, CDCl3) d: 8.50 (s, 1H, CH arom.); 8.05 (d,
J¼ 8.8 Hz, 2H, CH arom.); 8.00 (d, J¼ 8.8 Hz, 2H, CH arom.); 7.58 (d,
J¼ 16.0 Hz, 1H, CH]CH); 7.54e7.45 (m, 4H, CH arom.); 6.72 (s, 2H,
CH arom.); 6.35 (d, 1H, J¼ 16.0 Hz, CH]CH); 4.65 (dd, J¼ 10.8 Hz,
J¼ 4.4 Hz, 1H, OCHH); 4.49 (dd, J¼ 10.8 Hz, J¼ 6.0 Hz, 1H, OCHH);
4.19 (t, J¼ 6.4 Hz, 2H, OCH2); 3.86 (s, 3H, OCH3); 3.83 (s, 6H, OCH3);
2.42e2.30 (m, 3H, NCHH and NCH2); 2.22 (s, 3H, NCH3); 2.25e2.15
(m, 2H, NCHH and CH); 1.72e1.65 (m, 2H, CH2); 1.53e1.42 (m, 4H,
CH2); 1.06 (d, J¼ 6.4 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 169.86 (C]O); 167.08 (C]O); 153.38
(C); 144.62 (CH]CH); 139.97 (C); 130.98 (C); 129.95 (C); 129.17 (CH
arom); 128.61 (CH arom); 128.39 (C); 126.88 (CH arom); 125.47 (CH
arom); 125.11 (CH arom); 117.47 (CH]CH); 105.15 (CH arom); 69.32
(CH2); 64.60 (CH2); 61.25 (CH2); 60.97 (OCH3); 58.13 (CH2); 56.10
(OCH3); 42.76 (NCH3); 31.23 (CH); 28.70 (CH2); 26.99 (CH2); 23.85
(CH2); 16.08 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C37H44NO7¼614.3112, found 614.3117.
Hydrochloride: mp 88e99 C.
6.1.15.19. (R) (E)-7-(methyl(2-methyl-3-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)propyl)amino) heptyl 3,4,5-trimethoxybenzoate (R)-9.
Procedure B, starting from (R)-34 and 3,4,5-trimethoxybenzoic
acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH 97:3. Yield:
21%.
1H NMR (400MHz, CDCl3) d: 7.58 (d, J¼ 15.6 Hz, 1H, CH]CH);
7.28 (s, 2H, CH arom.); 6.74 (s, 2H, CH arom); 6.33 (d, J¼ 15.6 Hz,1H,
CH]CH); 4.28 (t, J¼ 6.8 Hz, 2H, OCH2); 4.23 (dd, J¼ 10.8 Hz,
J¼ 5.2 Hz, 1H, OCHH); 4.05 (dd, J¼ 10.8 Hz, J¼ 6.4 Hz, 1H, OCHH);
3.89 (s, 9H, OCH3); 3.88 (s, 6H, OCH3); 3.87 (s, 3H, OCH3); 2.47e2.43
(m, 3H, NCHH and NCH2); 2.31 (s, 3H, NCH3); 2.30e2.26 (m, 1H,
NCHH); 2.19e2.09 (m, 1H, CH); 1.70e1.59 (m, 2H, CH2); 1.48e1.29
(m, 8H, CH2); 1.03 (d, J¼ 6.4 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 167.00 (C]O); 166.27 (C]O); 153.45
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117.26 (CH]CH); 106.83 (CH arom.); 105.29 (CH arom.); 67.92
(CH2); 65.18 (CH2); 60.96 (CH2); 60.67 (OCH3); 57.76 (CH2); 56.10
(OCH3); 42.19 (NCH3); 30.87 (CH); 29.16 (CH2) 28.69 (CH2) 27.26
(CH2) 25.97 (CH2) 16.03 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C34H50NO10¼ 632.3429, found 632.3434.
Hydrochloride: mp 67e70 C.
6 .1.15 . 2 0 . ( S ) ( E ) - 7 - (me t h y l ( 2 -me t hy l - 3 - ( ( 3 - ( 3 , 4 , 5 -
trimethoxyphenyl)acryloyl)oxy)propyl)amino) heptyl 3,4,5-
trimethoxybenzoate (S)-9. Procedure A, starting from (S)-34 and
3,4,5-trimethoxybenzoic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH 95:5. Yield:
77%.
1H NMR (400MHz, CDCl3) d: 7.58 (d, J¼ 16.0 Hz, 1H, CH]CH);
7.28 (s, 2H, CH arom.); 6.75 (s, 2H, CH arom); 6.34 (d, J¼ 16.0 Hz,1H,
CH]CH); 4.29 (t, J¼ 6.8 Hz, 2H, OCH2); 4.24 (dd, J¼ 10.8 Hz,
J¼ 4.4 Hz, 1H, OCHH); 4.02 (dd, J¼ 10.8 Hz, J¼ 6.8 Hz, 1H, OCHH);
3.90 (s, 9H, OCH3); 3.88 (s, 6H, OCH3); 3.87 (s, 3H, OCH3); 2.40e2.25
(m, 3H, NCHH and NCH2); 2.20 (s, 3H, NCH3); 2.19e2.03 (m, 2H,
NCHH and CH); 1.77e1.71 (m, 2H, CH2); 1.50e1.24 (m, 8H, CH2);
1.00 (d, J¼ 6.4 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 167.04 (C]O); 166.27 (C]O); 153.45
(C); 152.92 (C); 144.61 (CH]CH); 142.80 (C); 140.30 (C); 129.93 (C);
125.54 (C); 117.42 (CH]CH); 106.83 (CH arom.); 105.27 (CH arom.);
68.11 (CH2); 65.23 (CH2); 61.23 (CH2); 60.96 (OCH3); 60.90 (OCH3);
58.25 (CH2); 56.25 (OCH3); 56.18 (OCH3); 42.71 (NCH3); 31.22 (CH);
29.23 (CH2); 28.72 (CH2); 27.30 (CH2); 26.00 (CH2); 15.93 (CH3)
ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C34H50NO10¼ 632.3429, found 632.3430.
Hydrochloride: mp 71e75 C.
6.1.15.21. (R) (E)-7-(methyl(2-methyl-3-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)propyl)amino) heptyl anthracene-9-carboxylate (R)-10.
Procedure B, starting from (R)-34 and anthracene-9-carboxylic
acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH 97:3. Yield:
58%.
1H NMR (400MHz, CDCl3) d: 8.51 (s, 1H, CH arom.); 8.05e8.00
(m, 4H, CH arom.); 7.59 (d, J¼ 16.0 Hz, 1H, CH]CH); 7.55e7.46 (m,
4H, CH arom.); 6.74 (s, 2H, CH arom); 6.35 (d, J¼ 16.0 Hz, 1H, CH]
CH); 4.60 (t, J¼ 6.4 Hz, 2H, OCH2); 4.24 (dd, J¼ 10.8 Hz, J¼ 4.8 Hz,
1H, OCHH); 4.03 (dd, J¼ 10.8 Hz, J¼ 6.4 Hz, 1H, OCHH); 3.87 (s, 3H,
OCH3); 3.86 (s, 6H, OCH3); 2.33e2.28 (m, 3H, NCH2 and NCHH); 2.18
(s, 3H, NCH3); 2.17e2.06 (m, 2H, NCHH and CH); 1.91e1.83 (m, 2H,
CH2); 1.53e1.30 (m, 8H, CH2); 1.00 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 167.08 (C]O); 153.41 (C); 144.52 (CH]
CH); 131.00 (C); 129.95 (C); 129.17 (CH arom.); 128.63 (CH arom.);
128.42 (C); 126.88 (CH arom.); 125.43 (CH arom.); 125.04 (CH
arom.); 117.51 (CH]CH); 105.22 (CH arom.); 68.25 (CH2); 65.90
(CH2); 61.32 (CH2); 60.99 (OCH3); 58.25 (CH2); 56.21 (OCH3); 42.72
(NCH3); 31.28 (CH); 29.25 (CH2); 28.75 (CH2); 27.35 (CH2); 26.12
(CH2); 15.89 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C39H48NO7¼642.3425, found 642.3425.
Hydrochloride: mp 100e103 C.
6 .1.15 . 2 2 . ( S ) ( E ) - 7 - (me t h y l ( 2 -me t hy l - 3 - ( ( 3 - ( 3 , 4 , 5 -
trimethoxyphenyl)acryloyl)oxy)propyl)amino) heptyl anthracene-9-
carboxylate (S)-10. Procedure B, starting from (S)-34 and anthra-
cene-9-carboxylic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
93:7:0.3. Yield: 46%.1H NMR (400MHz, CDCl3) d: 8.51 (s, 1H, CH arom.); 8.05e8.00
(m, 4H, CH arom); 7.59 (d, J¼ 16.0 Hz, 1H, CH]CH); 7.55e7.46 (m,
4H, CH arom.); 6.74 (s, 2H, CH arom); 6.35 (d, J¼ 16.0 Hz, 1H, CH]
CH); 4.61 (t, J¼ 6.8 Hz, 2H, OCH2); 4.25 (dd, J¼ 10.8 Hz, J¼ 4.8 Hz,
1H, OCHH); 4.03 (dd, J¼ 10.8 Hz, J¼ 6.8 Hz, 1H, OCHH); 3.87 (s, 3H,
OCH3); 3.86 (s, 6H, OCH3); 2.35e2.28 (m, 3H, NCHH and NCH2); 2.19
(s, 3H, NCH3); 2.17e2.02 (m, 2H, NCHH and CH); 1.91e1.84 (m, 2H,
CH2); 1.53e1.30 (m, 8H, CH2); 0.99 (d, J¼ 6.8 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 167.07 (C]O); 153.44 (C); 144.55 (CH]
CH); 131.01 (C); 129.96 (C); 129.19 (CH arom.); 128.61 (CH arom.);
128.39 (C); 126.90 (CH arom.); 125.45 (CH arom.); 125.03 (CH
arom.); 117.49 (CH]CH); 105.25 (CH arom.); 68.20 (CH2); 65.92
(CH2); 61.30 (CH2); 60.97 (OCH3); 58.28 (CH2); 56.17 (OCH3); 42.78
(NCH3); 31.30 (CH); 29.21 (CH2); 28.75 (CH2); 27.32 (CH2); 26.10
(CH2); 15.91 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C39H48NO7¼642.3425, found 642.3437.
Hydrochloride: mp 125e127 C.
6 .1.15 . 2 3 . ( R ) ( E ) - 2 -me t hy l - 3 - (me t hy l ( 7 - ( ( 3 - ( 3 , 4 , 5 -
trimethoxyphenyl)acryloyl)oxy)heptyl)amino)p ropyl 3,4,5-
trimethoxybenzoate (R)-11. Procedure B, starting from (R)-35 and
((E)-3-(3,4,5-trimethoxyphenyl)acrylic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH 98:2. Yield:
41%.
1H NMR (400MHz, CDCl3) d: 7.54 (d, J¼ 15.6 Hz, 1H, CH]CH);
7.25 (s, 2H, CH arom.); 6.71 (s, 2H, CH arom.); 6.30 (d, J¼ 15.6 Hz,
1H, CH]CH); 4.30 (dd, J¼ 10.8 Hz, J¼ 4.8 Hz, 1H, OCHH); 4.15e4.07
(m, 3H, OCH2 and OCHH); 3.85 (s, 9H, OCH3); 3.83 (s, 6H, OCH3);
3.82 (s, 3H, OCH3); 2.33e2.27 (m, 3H, NCH2 and NCHH); 2.18 (s, 3H,
NCH3); 2.17e2.11 (m, 2H, NCHH and CH); 1.65e1.59 (m, 2H, CH2);
1.42e1.20 (m, 8H, CH2); 0.98 (d, J¼ 6.4 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 167.02 (C]O); 166.21 (C]O); 153.42
(C); 152.92 (C); 144.55 (CH]CH); 129.95 (C); 125.51 (C); 117.49
(CH]CH); 106.79 (CH arom.); 105.22 (CH arom.); 68.53 (CH2);
64.63 (CH2); 61.28 (CH2); 60.94 (OCH3); 60.89 (OCH3); 58.30 (CH2);
56.21 (OCH3); 56.15 (OCH3); 42.78 (NCH3); 31.30 (CH); 29.21 (CH2);
28.70 (CH2); 27.29 (CH2); 27.18 (CH2); 25.95 (CH2); 15.98 (CH3)
ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C34H50NO10¼ 632.3429, found 632.3420.
Hydrochloride: mp 81e85 C.
6.1.15.24. (S) (E)-2-methyl-3-(methyl(7-((3-(3,4,5-trimethoxyphenyl)
acryloyl)oxy)heptyl)amino) propyl 3,4,5-trimethoxybenzoate (S)-11.
Procedure B, starting from (S)-35 and ((E)-3-(3,4,5-
trimethoxyphenyl)acrylic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH 98:2. Yield:
27%.
1H NMR (400MHz, CDCl3) d: 7.55 (d, J¼ 16.0 Hz, 1H, CH]CH);
7.26 (s, 2H, CH arom.); 6.72 (s, 2H, CH arom.); 6.31 (d, J¼ 16.0 Hz,
1H, CH]CH); 4.31 (dd, J¼ 10.8 Hz, J¼ 4.8 Hz, 1H, OCHH); 4.16e4.09
(m, 3H, OCH2 and OCHH); 3.86 (s, 9H, OCH3); 3.85 (s, 6H, OCH3);
3.84 (s, 3H, OCH3); 2.40e2.30 (m, 3H, NCH2 and NCHH); 2.22 (s, 3H,
NCH3); 2.21e2.10 (m, 2H, NCHH and CH); 1.66e1.61 (m, 2H, CH2);
1.50e1.40 (m, 2H, CH2); 1.39e1.20 (m, 6H, CH2); 1.01 (d, J¼ 6.4 Hz,
3H, CH3) ppm.
13C APT NMR (CDCl3) d: 167.05 (C]O); 166.22 (C]O); 153.43
(C); 152.94 (C); 144.57 (CH]CH); 129.96 (C); 125.48 (C); 117.49
(CH]CH); 106.82 (CH arom.); 105.23 (CH arom.); 68.50 (CH2);
64.64 (CH2); 61.18 (CH2); 60.96 (OCH3); 60.91 (OCH3); 58.22 (CH2);
56.23 (OCH3); 56.16 (OCH3); 42.69 (NCH3); 31.24 (CH); 29.21 (CH2);
28.71 (CH2); 27.29 (CH2); 25.95 (CH2); 16.03 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C34H50NO10¼ 632.3429, found 632.3429.
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6 .1.15 . 2 5 . ( R ) ( E ) - 2 -me t h y l - 3 - (me t h y l ( 7 - ( ( 3 - ( 3 , 4 , 5 -
trimethoxyphenyl)acryloyl)oxy)heptyl)amino) propyl anthracene-9-
carboxylate (R)-12. Procedure B, starting from (R)-36 and ((E)-3-
(3,4,5-trimethoxyphenyl)acrylic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
93:7:0.3. Yield: 77%.
1H NMR (400MHz, CDCl3) d: 8.48 (s, 1H, CH arom.); 8.02 (d,
J¼ 8.4 Hz, 2H, CH arom.); 7.98 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.56 (d,
J¼ 16.0 Hz, 1H, CH]CH); 7.51e7.43 (m, 4H, CH arom.); 6.71 (s, 2H,
CH arom.); 6.31 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.60 (dd, J¼ 10.8 Hz,
J¼ 4.4 Hz, 1H, OCHH); 4.47 (dd, J¼ 10.8 Hz, J¼ 5.6 Hz, 1H, OCHH);
4.15 (t, J¼ 6.8 Hz, 2H, OCH2); 3.84 (s, 3H, OCH3); 3.83 (s, 6H, OCH3);
2.45e2.35 (m, 3H, NCH2 and NCHH); 2.24 (s, 3H, NCH3); 2.24e2.22
(m, 2H, NCHH and CH); 1.66e1.61 (m, 2H, CH2); 1.48e1.37 (m, 2H,
CH2); 1.36e1.20 (m, 6H, CH2); 1.06 (d, J¼ 6.4 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 169.80 (C]O); 167.06 (C]O); 153.42
(C); 144.57 (CH]CH); 131.01 (C); 129.96 (C); 129.20 (CH arom.);
128.61 (CH arom.); 128.42 (C); 126.89 (CH arom.); 125.47 (CH
arom.); 125.11 (CH arom.); 117.51 (CH]CH); 105.23 (CH arom.);
69.26 (CH2); 64.66 (CH2); 60.95 (CH2); 58.12 (CH2); 56.15 (OCH3);
42.56 (NCH3); 31.09 (CH); 29.18 (CH2); 28.72 (CH2); 27.29 (CH2);
26.80 (CH2); 25.95 (CH2); 16.15 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C39H48NO7¼642.3425, found 642.3425.
Hydrochloride: mp 67e73 C.
6 .1.15 . 2 6 . ( S ) ( E ) - 2 -me t h y l - 3 - (me t hy l ( 7 - ( ( 3 - ( 3 , 4 , 5 -
trimethoxyphenyl)acryloyl)oxy)heptyl)amino) propyl anthracene-9-
carboxylate (S)-12. Procedure B, starting from (R)-36 and ((E)-3-
(3,4,5-trimethoxyphenyl)acrylic acid.
Free base: chromatographic eluent: CH2Cl2/CH3OH 98:2. Yield:
29%.
1H NMR (400MHz, CDCl3) d: 8.47 (s, 1H, CH arom.); 8.01 (d,
J¼ 8.4 Hz, 2H, CH arom.); 7.97 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.56 (d,
J¼ 16.0 Hz, 1H, CH]CH); 7.51e7.42 (m, 4H, CH arom.); 6.70 (s, 2H,
CH arom.); 6.31 (d, J¼ 16.0 Hz, 1H, CH]CH); 4.60 (dd, J¼ 10.8 Hz,
J¼ 4.4 Hz, 1H, OCHH); 4.46 (dd, J¼ 10.8 Hz, J¼ 6.0 Hz, 1H, OCHH);
4.15 (t, J¼ 6.8 Hz, 2H, OCH2); 3.84 (s, 3H, OCH3); 3.82 (s, 6H, OCH3);
2.45e2.30 (m, 3H, NCH2 and NCHH); 2.22 (s, 3H, NCH3); 2.22e2.20
(m, 2H, NCHH and CH); 1.67e1.61 (m, 2H, CH2); 1.48e1.20 (m, 8H,Table 4
Elution conditions employed to carry out the resolution of racemic mixtures of compoun
Racemic mixture Mobile pha
(R)-1/(S)-1, (R)-3/(S)-3, (R)-5/(S)-5, (R)-9/(S)-9, (R)-11/(S)-11 A
(R)-2/(S)-2 B
(R)-6/(S)-6, (R)-10/(S)-10 C
(R)-8/(S)-8 D
a methanol:isopropanol 60:40 (v/v), with 0.1% of DEA; B: methanol:acetonitrile 95:5
methanol:acetonitrile 98:2 (v/v), with 0.1% of DEA.
Table 5
Retention time (TR), ee values and resolution (R) between the enantiomers of compoun
Compd TR (min) ee % R value
(R)-1 22.28± 0.02 95 2.18± 0.04
(S)-1 19.36± 0.03 95
(R)-2 16.47± 0.05 95 1.22± 0.04
(S)-2 14.73± 0.04 95
(R)-3 19.70± 0.20 95 1.43± 0.03
(S)-3 21.70± 0.20 95
(R)-5 22.70± 0.60 95 2.78± 0.05
(S)-5 19.10± 0.50 95CH2); 1.05 (d, J¼ 6.0 Hz, 3H, CH3) ppm.
13C APT NMR (CDCl3) d: 169.79 (C]O); 167.04 (C]O); 153.42
(C); 144.55 (CH]CH); 131.00 (C); 129.97 (C); 129.18 (CH arom.);
128.60 (CH arom.); 128.41 (C); 128.28 (C); 126.87 (CH arom.);
125.46 (CH arom.); 125.11 (CH arom.); 117.52 (CH]CH); 105.24 (CH
arom.); 69.27 (CH2); 64.65 (CH2); 61.13 (CH2); 60.95 (OCH3); 58.27
(CH2); 56.14 (OCH3); 42.69 (NCH3); 31.17 (CH); 29.19 (CH2); 28.73
(CH2); 27.28 (CH2); 25.96 (CH2); 16.12 (CH3) ppm.
ESI-HRMS (m/z) calculated for [MþH]þ ion species
C39H48NO7¼642.3425, found 642.3415.
Hydrochloride: mp 84e89 C.
6.1.16. Enantiomeric excess (ee) of (R) and (S) enantiomers
evaluation
The separation of racemic mixture of the studied compounds
was carried out by Agilent 1200 liquid chromatography system
composed by autosampler, binary pumps, column oven and diode-
array detector (LC-DAD) operating in UV range (210e400 nm). The
analyses were performed by using a Phenomenex Lux Cellulose-3
column 250mm length, 4.6mm internal diameter and 5 mm par-
ticle size, in isocratic elution. The sample injection volume was
20 mL. The elution conditions employed to carry out the resolution
of racemic mixtures of compounds 1, 2, 3, 5, 6, 8, 9, 10 and 11 are
reported in Table 4 and the Retention Time (TR), ee values and
resolution (R) between the enantiomers of the same compounds
are reported in Table 5.
6.2. Biological assay
6.2.1. Cell lines and cultures
The K562 is an undifferentiated erythroleukemia cell line orig-
inally derived from a patient with chronic myelogenous leukemia
[48]. The K562 leukemia cells and the P-gp over-expressing K562/
DOX cells were obtained from Prof. J.P. Marie (Hopital Hotel-Dieu,
Paris, France). The cells were cultured following a previously re-
ported protocol [67].
MDCK-MDR1, MDCK-MRP1 and MDCK-BCRP cells are a gift of
Prof. P. Borst, NKI-AVL Institute, Amsterdam, Nederland. MDCK cells
were grown in DMEM high glucose supplemented with 10% fetal
bovine serum, 2mM glutamine, 100 U/mL penicillin, 100 mg/mL
streptomycin, in a humidified incubator at 37 C with a 5% CO2
atmosphere. Caco-2 cells were a gift of Dr. Aldo Cavallini and Dr.ds 1, 2, 3, 5, 6, 8, 9, 10 and 11.
sea Flow (mL min1) T (C) UV (nm)
0.5 20 300
0.8 10 250
0.8 20 250
0.5 20 250
(v/v), with 0.1% of DEA; C: methanol:acetonitrile 90:10 (v/v), with 0.1% of DEA; D:
ds 1, 2, 3, 5, 6, 8, 9, 10 and 11.
Compd TR (min) ee % R value
(R)-6 12.02± 0.01 95 3.88± 0.01
(S)-6 9.27± 0.01 95
(R)-8 23.22± 0.06 95 1.18± 0.01
(S)-8 24.80± 0.07 95
(R)-9 22.72± 0.02 95 1.89± 0.05
(S)-9 20.13± 0.02 95
(R)-10 11.01± 0.01 95 3.12± 0.01
(S)-10 9.11± 0.01 95
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Institute for Digestive Diseases, “S. de Bellis”, Bari (Italy).
6.2.2. Drugs and materials
Purified verapamil and pirarubicin were purchased by Sigma-
Aldrich (Milan - Italy). Concentrations were determined by
diluting stock solutions to approximately 105M and using
ε480¼11500M1 cm1. Stock solutions were prepared just before
use. Buffer solutions were HEPES buffer containing 5mM HEPES,
132mM NaCl, 3.5mM CaCl2, 5mM glucose, at pH 7.3.
Cell culture reagents were purchased from Celbio s.r.l. (Milano,
Italy). CulturePlate 96/wells plates were purchased from Perki-
nElmer Life Science; Calcein-AM, bisBenzimide H 33342 trihydro-
chloride were obtained from Sigma-Aldrich (Milan, Italy).
6.2.3. Modulation of pirarubicin uptake on K562/DOX cells
The uptake of pirarubicin in cells was followed by monitoring
the decrease in the fluorescence signal at 590 nm (lex¼ 480 nm)
according to the previously described method [68,69].
6.2.4. Characterization of P-gp interacting profile and ABC
transporters selectivity on transfected MDCK cells
Calcein-AM and Hoechst 33342 experiments, ATPlite assay and
Permeability experiments were carried out as previously described
[42]. Details are reported in the Supplementary data.
6.2.5. Antiproliferative assay
Determination of cell growth was performed using the MTT
assay at 48 h and 72 h [70]. Data were analysed by one-way ANOVA
for repeated measures. Results are expressed as mean± SD of at
2e3 independent experiments in triplicates. Statistical significance
was accepted at a level of P< 0.05. Details are reported in the
Supplementary data.
6.2.6. Co-administration assay
The co-administration assay with doxorubicinwas performed in
MDCK-MDR1 cells at 48 h as reportedwithminormodification [71].
Details are reported in the Supplementary data.
6.2.7. Collateral sensitivity (CS) study
All the compounds have been tested for their cytotoxic activity
at 24 h on MDCK-MDR1 and MDCK-MRP1 cells and on the parental
MDCK cells by MTT assay.
To evaluate the mechanisms involved in CS, reactive oxygen
species (ROS) were measured using the fluorescent probe 5-(and-
6)-chloromethyl-20,70-dichlorodihydro-fluorescein diacetate-
acetoxymethyl ester (DCFDA-AM), as previously reported [72].
The results were expressed as nmoles/mg cellular proteins. Cell
viability with the compounds and ROS scavenger was measured by
the ATPlite Luminescence Assay System (PerkinElmer, Waltham,
MA), as per manufacturer's instructions, using a Synergy HT Multi-
Detection Microplate Reader (BioTek Instruments, Winooski, VT).
The relative luminescence units (RLU) of untreated cells were
considered as 100% viability; results were expressed as a percent-
age of viable cells versus untreated cells.
6.3. Molecular docking studies
The crystal structure of human P-gp with in the ATP-bound,
outward-facing conformation (PDB ID: 6C0V) [52], was down-
loaded from PDB database.
The molecular structures of synthesized compounds were
designed with Chemdraw program, and then optimized prior to
docking procedure, by using the Dock Prep application.
In order to prepare the ligands and receptor for dockingcalculation, MolSoft was used [51], then for each compound, the
molecular docking study was carried out by the software. The grid
box was set to 20Å 20 Å 28 Åwith a grid space value of 1 Å. The
binding box was centred at the previously reported helix TM4
(W232), TM5 (R296, I299, I306), TM6 (Y310, F336), TM7 (F928),
TM8 (F303, Y307, F770) and TM12 (M986, Q990, F994), involved in
the substrate-binding region [73e76]. MolSoft program was used
setting default parameters and a maximum of 50 poses per ligand
were collected. The results were analysed using PyMOL v2.0 [77]. To
find network of interaction we used Ligplot þ v.1.4.5 [78] and
Protein-Ligand Interaction Profiler [79] all the sets were by default.
6.4. Stability test
6.4.1. Chemicals
Acetonitrile (Chromasolv), formic acid and ammonium formate
(MS grade), NaCl, KCl, Na2HPO4 2H2O, KH2PO4 (Reagent grade) and
verapamil hydrochloride (analytical standard, used as internal
standard), ketoprofen and enalapril (analytical standard) were
purchased by Sigma-Aldrich (Milan, Italy). Ketoprofen Ethyl Ester
(KEE) were obtained by Fisher's reaction from ketoprofen and
ethanol.
MilliQ water 18MU cm1 was obtained from Millipore's
Simplicity system (Milan - Italy).
Phosphate buffer solution (PBS) was prepared by adding
8.01 g L1 of NaCl, 0.2 g L1 of KCl, 1.78 g L1 of Na2HPO4 2H2O and
0.27 g L1 of KH2PO4. Human plasma was collected from healthy
male volunteer and kept at 80 C until use.
6.4.2. Preparation of samples
Each sample was prepared adding 10 mL of working solution
1e100 mL of tested matrix (PBS or rat plasma or human plasma) in
microcentrifuge tubes. The obtained solutions correspond to 1 mM
of analyte.
Each set of samples was incubated in triplicate at four different
times, 0, 30, 60 and 120min at 37 C. Therefore, the degradation
profile of each analyte was represented by a batch of 12 samples (4
incubation times x 3 replicates). After the incubation, the samples
were added with 300 mL of ISTD solution and centrifuged (room
temperature for 5min at 10000 rpm). The supernatants were
transferred in autosampler vials and dried under a gentle stream of
nitrogen.
The dried samples were dissolved in 1.0mL of 10mM of formic
acid in mQ water:acetonitrile 80:20 solution. The obtained sample
solutions were analysed by LC-MS/MS method described in the
Supplementary data.
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